<article article-type="review-article" dtd-version="1.4" xml:lang="en"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">JHEP Rep</journal-id><journal-id journal-id-type="iso-abbrev">JHEP Rep</journal-id><journal-id journal-id-type="pmc-domain-id">3793</journal-id><journal-id journal-id-type="pmc-domain">jhepr</journal-id><journal-title-group><journal-title>JHEP Reports</journal-title></journal-title-group><issn pub-type="epub">2589-5559</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12890451</article-id><article-id pub-id-type="pmcid-ver">PMC12890451.1</article-id><article-id pub-id-type="pmcaid">12890451</article-id><article-id pub-id-type="pmcaiid">12890451</article-id><article-id pub-id-type="pmid">41674895</article-id><article-id pub-id-type="doi">10.1016/j.jhepr.2025.101625</article-id><article-id pub-id-type="pii">S2589-5559(25)00307-6</article-id><article-id pub-id-type="publisher-id">101625</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Challenges in the diagnosis and treatment of genetic cholestasis in adults</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name name-style="western"><surname>Thompson</surname><given-names initials="RJ">Richard J.</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author" id="au2"><name name-style="western"><surname>Vilarinho</surname><given-names initials="S">Silvia</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author" id="au3"><name name-style="western"><surname>Miquel</surname><given-names initials="R">Rosa</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author" id="au4"><name name-style="western"><surname>Keitel</surname><given-names initials="V">Verena</given-names></name><email>verena.keitel-anselmino@med.ovgu.de</email><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="corresp" rid="cor1">⁎</xref></contrib><aff id="aff1"><label>1</label>Roger Williams Institute of Liver Studies, King's College London, London, UK</aff><aff id="aff2"><label>2</label>Department of Internal Medicine, Section of Digestive Diseases, Yale School of Medicine, New Haven, Connecticut, USA</aff><aff id="aff3"><label>3</label>Departments of Genetics and Pathology, Yale School of Medicine, New Haven, Connecticut, USA</aff><aff id="aff4"><label>4</label>Institute of Liver Studies, Liver Histopathology Laboratory, King's College Hospital, London, UK</aff><aff id="aff5"><label>5</label>Department of Gastroenterology, Hepatology and Infectious Diseases, University Hospital Magdeburg Otto von Guericke University, Magdeburg, Germany</aff></contrib-group><author-notes><corresp id="cor1"><label>⁎</label>Corresponding author. Address: Department of Gastroenterology, Hepatology and Infectious Diseases, University Hospital Magdeburg Otto von Guericke University, Magdeburg, Germany. <email>verena.keitel-anselmino@med.ovgu.de</email></corresp></author-notes><pub-date pub-type="collection"><month>1</month><year>2026</year></pub-date><pub-date pub-type="epub"><day>09</day><month>10</month><year>2025</year></pub-date><volume>8</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">502434</issue-id><elocation-id>101625</elocation-id><history><date date-type="received"><day>30</day><month>4</month><year>2025</year></date><date date-type="rev-recd"><day>25</day><month>9</month><year>2025</year></date><date date-type="accepted"><day>29</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>09</day><month>10</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>11</day><month>02</month><year>2026</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2026-02-12 09:25:12.830"><day>12</day><month>02</month><year>2026</year></date></event></pub-history><permissions><copyright-statement>© 2025 The Authors</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref content-type="ccbylicense" specific-use="textmining" xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="main.pdf" xmlns:xlink="http://www.w3.org/1999/xlink"/><abstract id="abs0010"><title>Summary</title><p>Disorders of bile formation and bile flow along the intra- and extrahepatic bile ducts are summarised under the term cholestasis. Clinically, conditions resulting in retention of biliary constituents such as bile acids within hepatocytes (termed primary cholestasis) need to be distinguished from diseases characterised by bile duct injury (termed cholangiopathies). Some cholangiopathies may also cause retention of biliary constituents within hepatocytes, resulting in secondary cholestasis. Genetic variants in a multitude of genes can contribute to the development of both primary cholestasis and cholangiopathies. Assessing the contribution of identified genetic variants to the clinical presentation in adults is complicated by factors such as environmental exposure, comorbidities, and medication intake. The diagnostic workup in adults with cholestasis should first consider common causes of primary cholestasis and cholangiopathies. If the aetiology remains unclear, liver histology and/or genetic testing should be pursued. Until recently, treatment for these conditions was largely supportive. However pharmacological interruption of the enterohepatic circulation of bile acids now offers the possibility of more specific intervention. Moreover, for those conditions in which the bile duct epithelium is the main site of injury, ursodeoxycholic acid remains essential. Multidisciplinary case discussions can help facilitate diagnosis and guide management.</p></abstract><abstract abstract-type="graphical" id="abs0015"><title>Graphical abstract</title><p><fig id="undfig1" orientation="portrait" position="anchor"><alt-text id="alttext0010">Image 1</alt-text><graphic orientation="portrait" position="float" xlink:href="ga1.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/></fig></p></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>Primary cholestasis</kwd><kwd>cholangiopathy</kwd><kwd>gamma glutamyl transferase</kwd><kwd>bile acids</kwd><kwd>bile salt export pump</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p id="p0010">
<boxed-text id="dtbox1" orientation="portrait" position="float"><caption><title>Keypoints</title></caption><p id="p0015">
<list id="ulist0010" list-type="simple"><list-item id="u0010"><label>•</label><p id="p0020">Genetic defects are increasingly recognised as causative or relevant contributing factors in adult primary cholestasis and cholangiopathies.</p></list-item><list-item id="u0015"><label>•</label><p id="p0025">Primary cholestasis is defined by retention of biliary constituents such as bile acids within hepatocytes, leading to elevation of serum bile acids despite normal/low gamma-glutamyltransferase levels.</p></list-item><list-item id="u0020"><label>•</label><p id="p0030">Cholangiopathies are characterised by injury of the bile ducts and usually associated with an elevation of serum gamma-glutamyltransferase levels.</p></list-item><list-item id="u0025"><label>•</label><p id="p0035">A stepwise diagnostic approach with initial assessment of common causes of cholestasis, followed by liver biopsy and genetic testing if aetiology remains unclear, is suggested.</p></list-item><list-item id="u0030"><label>•</label><p id="p0040">Multidisciplinary case discussions help to facilitate diagnosis and therapeutic management.</p></list-item><list-item id="u0035"><label>•</label><p id="p0045">Treatment of the underlying pathology is not yet possible for genetic cholestasis; however, therapeutic management should alleviate the consequences of cholestasis and include symptom control.</p></list-item></list>
</p></boxed-text>
</p><sec id="sec1"><title>Introduction</title><p id="p0050">Cholestasis refers to impaired bile formation or disrupted bile flow through the biliary tree into the small intestine. Bile formation involves the synthesis of its constituents, their transport across the canalicular membrane, and movement through the biliary tree.<xref ref-type="bibr" rid="bib1"><sup>1</sup></xref> Mutations in genes vital for the transport of biliary constituents and/or the stability/composition of the apical membranes of hepatocytes and cholangiocytes have been identified in patients with progressive familial intrahepatic cholestasis (PFIC), a severe group of disorders that present in early infancy with jaundice, failure to thrive, pruritus and progressive cholestatic liver disease.<xref ref-type="bibr" rid="bib2"><sup>2</sup></xref> Genetic cholestatic liver diseases have long been considered primarily paediatric disorders, as they were initially described in children. However, with advances in next-generation sequencing technologies and the adoption of whole-exome sequencing (WES) in clinical hepatology,<xref ref-type="bibr" rid="bib3"><sup>3</sup></xref> it has become evident that these diseases can also present in adulthood. Several studies have demonstrated that a substantial proportion of adults with unexplained cholestasis, despite comprehensive evaluation, harbour genetic defects that explain their condition.<xref ref-type="bibr" rid="bib4">[4]</xref>, <xref ref-type="bibr" rid="bib5">[5]</xref>, <xref ref-type="bibr" rid="bib6">[6]</xref>, <xref ref-type="bibr" rid="bib7">[7]</xref>, <xref ref-type="bibr" rid="bib8">[8]</xref> The recognition of monogenic defects as the cause of cholestatic liver disease in adults has only recently gained attention. One of the challenges in adult genetic cholestasis is the broad spectrum of clinical presentations ranging from elevated liver enzymes, pruritus, infrequent symptoms precipitated by factors such as infection, hormonal status or drug intake to severe early-onset or late-onset progressive disease.<xref ref-type="bibr" rid="bib2"><sup>2</sup></xref> With broader application of genetic testing in liver diseases of unclear origin, genetic contributions will be increasingly identified.<xref ref-type="bibr" rid="bib4"><sup>4</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib5"><sup>5</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib7"><sup>7</sup></xref> However, determining the extent to which identified genetic variants contribute to the clinical presentation in adults is often challenging, as it is confounded by environmental factors, comorbidities, and medication use.</p><p id="p0055">In this review, we will examine the genetic contribution of PFIC-associated genes to adult primary cholestasis and cholangiopathies, and discuss current therapeutic approaches. Bile acid synthesis defects and cholestasis syndromes including Alagille syndrome, arthrogryposis–renal dysfunction–cholestasis, neonatal sclerosing cholangitis and osteo-oto-hepato-enteric syndrome are beyond the scope of this review and are summarised elsewhere.<xref ref-type="bibr" rid="bib9"><sup>9</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib10"><sup>10</sup></xref></p></sec><sec id="sec2"><title>Genes associated with hereditary cholestasis in adults</title><p id="p0060">The number of gene defects associated with severe primary cholestasis and cholangiopathies continues to increase due to broader availability of exome and genome sequencing technologies. Ibrahim <italic toggle="yes">et al.</italic><xref ref-type="bibr" rid="bib9"><sup>9</sup></xref> provide a comprehensive overview of the genes underlying a variety of monogenic cholestasis disorders. Mechanistically, genetic defects resulting in retention of biliary constituents such as bile acids (BAs) within hepatocytes (termed primary cholestasis, <xref ref-type="fig" rid="fig1">Fig. 1</xref>, <xref ref-type="fig" rid="fig2">Fig. 2</xref>A) will be distinguished from genetic defects characterised by bile duct injury (termed cholangiopathies, <xref ref-type="fig" rid="fig2">Fig. 2</xref>B).<fig id="fig1" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>Proteins expressed within the hepatocytes and associated with primary cholestasis (modified from<xref ref-type="bibr" rid="bib136"><sup>136</sup></xref>).</p><p>PFIC-associated genes encode hepatobiliary ATPases and transport proteins, such as the P-type ATPase FIC1 (<italic toggle="yes">ATP8B1</italic>), the bile salt export pump BSEP (<italic toggle="yes">ABCB11</italic>) and the phospholipid floppase MDR3 (<italic toggle="yes">ABCB4</italic>) as well as the nuclear receptor farnesoid X receptor (FXR). Moreover, components of the cell adhesion complex – such as tight junction protein 2 (TJP2/ZO-2), USP53, and LSR – as well as proteins involved in the intracellular trafficking of canalicular transporters, including myosin 5B (MYO5B), VSP33B, VIPAR, and semaphorin 7A (SEMA7A), may also contribute to genetic cholestasis. Bile acids transported by BSEP and phospholipids transported by MDR3 into bile form mixed micelles with cholesterol, which is excreted by ABCG5/G8. For references see text.</p></caption><alt-text id="alttext0020">Fig. 1</alt-text><graphic orientation="portrait" position="float" xlink:href="gr1.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/></fig><fig id="fig2" orientation="portrait" position="float"><label>Fig. 2</label><caption><p>Mechanisms of cholestasis taken from.<xref ref-type="bibr" rid="bib137"><sup>137</sup></xref></p><p>(A) Schematic representation of primary cholestasis exemplified by BSEP deficiency. Mutations in a variety of genes reduce the amount of functionally active BSEP within in the canalicular membrane resulting in intrahepatic retention of BAs and hepatocytic damage. (B) Schematic representations of ABCB4-disease. Reduction of phosphatidylcholine secretion into bile reduces the capacity to form mixed micelles leading to a relative increase in toxic bile acids. The latter triggers progressive cholangiocyte damage.</p></caption><alt-text id="alttext0025">Fig. 2</alt-text><graphic orientation="portrait" position="float" xlink:href="gr2.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/></fig></p><sec id="sec2.1"><title>Genes associated with low-GGT primary cholestasis</title><p id="p0065">Primary cholestasis is associated with genes encoding proteins affecting hepatobiliary transport protein expression (<italic toggle="yes">e.g</italic>. <italic toggle="yes">ABCB11, NR1H4</italic>), integrity of the canalicular membrane and tight junctions (<italic toggle="yes">e.g. ATP8B1, TJP2, USP53, LSR</italic>), and intracellular trafficking of hepatobiliary transport proteins (<italic toggle="yes">e.g. MYO5B, SEMA7A</italic>) (<xref ref-type="table" rid="tbl1">Table 1</xref>).<table-wrap id="tbl1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Genes associated with primary cholestasis and typically characterised by normal GGT levels (modified from<xref ref-type="bibr" rid="bib9"><sup>9</sup></xref>).</p></caption><alt-text id="alttext0040">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Gene</th><th colspan="1" rowspan="1">Protein</th><th colspan="1" rowspan="1">Clinical manifestation</th><th colspan="1" rowspan="1">Extrahepatic manifestations</th></tr></thead><tbody><tr><td colspan="1" rowspan="1"><italic toggle="yes">ATP8B1</italic></td><td colspan="1" rowspan="1">FIC1</td><td colspan="1" rowspan="1">PFIC, (episodic) cholestasis, ICP, elevated LFT, pruritus</td><td colspan="1" rowspan="1">Intestinal symptoms (diarrhoea), hearing loss, pancreatitis</td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">ABCB11</italic></td><td colspan="1" rowspan="1">BSEP</td><td colspan="1" rowspan="1">PFIC, episodic cholestasis, DILI, ICP, HCC, elevated LFT, gallstones, pruritus</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">TJP2</italic></td><td colspan="1" rowspan="1">TJP2</td><td colspan="1" rowspan="1">PFIC, episodic cholestasis, ICP, elevated LFT, gallstones, HCC, pruritus</td><td colspan="1" rowspan="1">Intestinal symptoms (diarrhoea), pancreatitis, hearing loss</td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">NR1H4</italic></td><td colspan="1" rowspan="1">FXR</td><td colspan="1" rowspan="1">PFIC, ICP, gallstones</td><td colspan="1" rowspan="1">Vitamin K-independent coagulopathy</td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">USP53</italic></td><td colspan="1" rowspan="1">USP53</td><td colspan="1" rowspan="1">PFIC</td><td colspan="1" rowspan="1">Hearing loss</td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">LSR</italic></td><td colspan="1" rowspan="1">LSR</td><td colspan="1" rowspan="1">PFIC</td><td colspan="1" rowspan="1">Speech and developmental delays</td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">Myosin5B</italic></td><td colspan="1" rowspan="1">Myosin5B</td><td colspan="1" rowspan="1">PFIC, MVID</td><td colspan="1" rowspan="1">MVID, intestinal symptoms, neurodevelopmental delay and pyramidal syndrome</td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">SEMA7A</italic></td><td colspan="1" rowspan="1">Semaphorin 7A</td><td colspan="1" rowspan="1">PFIC, ICP, MASLD</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">VPS33B</italic></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">ARC syndrome, but also incomplete ARC with predominant cholestasis</td><td colspan="1" rowspan="1">Kidney and bone disease</td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">VIPAS39</italic></td><td colspan="1" rowspan="1">VIPAR</td><td colspan="1" rowspan="1">ARC syndrome</td><td colspan="1" rowspan="1">Kidney and bone disease</td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">ABCC12</italic></td><td colspan="1" rowspan="1">MRP9</td><td colspan="1" rowspan="1">Cholestasis, ductopenia</td><td colspan="1" rowspan="1"/></tr></tbody></table><table-wrap-foot><fn><p>ARC, arthrogryposis–renal dysfunction–cholestasis; DILI, drug-induced liver injury; GGT, gamma-glutamyltransferase; HCC, hepatocellular carcinoma; ICP, intrahepatic cholestasis of pregnancy; LFT, liver function tests; MASLD, metabolic dysfunction-associated steatotic liver disease; MVID, microvillus inclusion disease; PFIC, progressive familial intrahepatic cholestasis.</p></fn></table-wrap-foot></table-wrap></p><sec id="sec2.1.1"><title>BSEP and FXR deficiencies</title><p id="p0070">BA excretion across the canalicular membrane is critically determined by the amount of functionally active bile salt export pump (BSEP), encoded by <italic toggle="yes">ABCB11,</italic> in the canalicular membrane of hepatocytes.<xref ref-type="bibr" rid="bib11"><sup>11</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib12"><sup>12</sup></xref> BSEP expression is regulated by the farnesoid X receptor (FXR, encoded by <italic toggle="yes">NR1H4</italic>).<xref ref-type="bibr" rid="bib13"><sup>13</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib14"><sup>14</sup></xref> Biallelic mutations in <italic toggle="yes">NR1H4</italic> or in <italic toggle="yes">ABCB11,</italic> leading to a major reduction in BSEP function in the liver, result in early-onset and rapidly progressive PFIC phenotypes, characterised by normal levels of serum gamma-glutamyltransferase (GGT) despite high serum BA levels.<xref ref-type="bibr" rid="bib11"><sup>11</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib15">[15]</xref>, <xref ref-type="bibr" rid="bib16">[16]</xref>, <xref ref-type="bibr" rid="bib17">[17]</xref>, <xref ref-type="bibr" rid="bib18">[18]</xref> In individuals of European descent, the two most common PFIC-associated BSEP variants are p.E297G and p.D482G, both of which retain some functional activity.<xref ref-type="bibr" rid="bib19"><sup>19</sup></xref> The presence of at least one of these two variants, along with another missense variant on the other allele, can prolong native liver survival compared to persons carrying biallelic predicted protein truncating variants (PPTMs) and may underlie late-onset PFIC or even less severe phenotypes like recurrent cholestasis.<xref ref-type="bibr" rid="bib7"><sup>7</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib8"><sup>8</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib17"><sup>17</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib18"><sup>18</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib20"><sup>20</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib21"><sup>21</sup></xref> Common variants in either <italic toggle="yes">NR1H4</italic> (-1G&gt;T, rs56163822) or <italic toggle="yes">ABCB11</italic> (p.V444A, rs2287622) combined with deleterious heterozygous <italic toggle="yes">ABCB11</italic> variants may reduce BSEP protein expression and transport capacity to levels that enable adequate transport of BAs across the canalicular membrane under normal conditions.<xref ref-type="bibr" rid="bib22">[22]</xref>, <xref ref-type="bibr" rid="bib23">[23]</xref>, <xref ref-type="bibr" rid="bib24">[24]</xref>, <xref ref-type="bibr" rid="bib25">[25]</xref> However, elevation of proinflammatory cytokines during bacterial or viral infections, elevation of progesterone and oestrogen levels during pregnancy, or intake of various drugs reduce already diminished BSEP levels further and thus below a threshold where BA secretion is impaired and cholestasis ensues.<xref ref-type="bibr" rid="bib2"><sup>2</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib26">[26]</xref>, <xref ref-type="bibr" rid="bib27">[27]</xref>, <xref ref-type="bibr" rid="bib28">[28]</xref>, <xref ref-type="bibr" rid="bib29">[29]</xref>, <xref ref-type="bibr" rid="bib30">[30]</xref></p></sec><sec id="sec2.1.2"><title>FIC1 deficiency</title><p id="p0075"><italic toggle="yes">ATP8B1</italic> encodes familial intrahepatic cholestasis 1 (FIC1), a P-type ATPase, which flips phosphatidylserine from the outer into the inner leaflet of the plasma membrane in many cells, including in the canalicular membrane of hepatocytes.<xref ref-type="bibr" rid="bib31">[31]</xref>, <xref ref-type="bibr" rid="bib32">[32]</xref>, <xref ref-type="bibr" rid="bib33">[33]</xref> FIC1 deficiency disturbs the lipid asymmetry within the canalicular membrane, affecting the transport activity of BSEP and rendering the membrane vulnerable to the detergent activity of BAs.<xref ref-type="bibr" rid="bib31"><sup>31</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib32"><sup>32</sup></xref> It has also been suggested that FIC1 affects trafficking of hepatobiliary transport proteins, which may also contribute to cholestasis development.<xref ref-type="bibr" rid="bib2"><sup>2</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib33"><sup>33</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib34"><sup>34</sup></xref> In contrast to BSEP deficiency, no correlation between mutation type (biallelic missense <italic toggle="yes">vs.</italic> biallelic PPTMs) and native liver survival has been observed so far.<xref ref-type="bibr" rid="bib17"><sup>17</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib35"><sup>35</sup></xref></p></sec><sec id="sec2.1.3"><title>TJP2 deficiency</title><p id="p0080">Tight junction protein 2 (TJP2, also known as zona occludens-2) isoforms are almost ubiquitously expressed in epithelial cells and form a link between the transmembrane components of the tight junction complexes, such as claudin-1 and claudin-2, and the actin cytoskeleton.<xref ref-type="bibr" rid="bib36"><sup>36</sup></xref> A missense mutation (p.V48A) in TJP2 was first identified in Amish persons presenting with hypercholanaemia characterised by pruritus, elevated serum BAs and fat malabsorption but without progressive liver disease.<xref ref-type="bibr" rid="bib37"><sup>37</sup></xref>
<italic toggle="yes">In vitro</italic> studies suggested that this variant impairs the interaction of TJP2 with claudins.<xref ref-type="bibr" rid="bib37"><sup>37</sup></xref> Subsequently, more damaging <italic toggle="yes">TJP2</italic> mutations were detected in patients with low-GGT PFIC.<xref ref-type="bibr" rid="bib38"><sup>38</sup></xref> Mice with liver-specific deletion of <italic toggle="yes">Tjp2</italic> developed a mild cholestatic phenotype, which was aggravated by cholic acid feeding. Mechanistically, canaliculi were dilated and Bsep levels at the canalicular membrane were reduced, resulting in elevated serum BA levels.<xref ref-type="bibr" rid="bib39"><sup>39</sup></xref> Induced pluripotent stem-cell-derived hepatocytes from a patient with TJP2 deficiency revealed distorted bile canaliculi and altered localisation of the apical and basolateral hepatobiliary transport proteins, including BSEP, resulting in impaired BA secretion across the apical membrane.<xref ref-type="bibr" rid="bib40"><sup>40</sup></xref> Similar to patients with BSEP deficiency, patients carrying biallelic TJP2 protein truncating variants suffer from a rapidly progressive phenotype.<xref ref-type="bibr" rid="bib17"><sup>17</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib41"><sup>41</sup></xref></p></sec><sec id="sec2.1.4"><title>USP53 deficiency</title><p id="p0085"><italic toggle="yes">USP53</italic> encoding ubiquitin carboxyl-terminal hydrolase 53 is another gene associated with low-GGT PFIC in different cohorts.<xref ref-type="bibr" rid="bib42"><sup>42</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib43"><sup>43</sup></xref> The function of USP53, which lacks deubiquitinase activity, and the pathophysiology underling USP53-associated cholestasis remain elusive.<xref ref-type="bibr" rid="bib43"><sup>43</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib44"><sup>44</sup></xref> Usp53 was shown to interact with Tjp2 in a mouse model and Bsep expression levels were reduced in the livers of hepatocyte-specific <italic toggle="yes">Usp53</italic> knockout mice.<xref ref-type="bibr" rid="bib45"><sup>45</sup></xref> Due to the more hydrophilic BA pool composition, mice deficient in PFIC-associated genes do not necessarily develop spontaneous (progressive) cholestasis and liver injury on a regular chow diet. However, BA feeding can trigger intrahepatic cholestasis and aggravate liver damage in some of these mouse models, including <italic toggle="yes">Bsep</italic>-, <italic toggle="yes">Fic1</italic>-and <italic toggle="yes">Fxr</italic>-deficient mice.<xref ref-type="bibr" rid="bib13"><sup>13</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib46"><sup>46</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib47"><sup>47</sup></xref> Notably, hepatocyte-specific <italic toggle="yes">Usp53</italic>-deficient mice did not develop significant cholestasis or liver injury after cholic acid feeding in contrast to the <italic toggle="yes">Tjp2</italic>-deficient animals.<xref ref-type="bibr" rid="bib39"><sup>39</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib45"><sup>45</sup></xref> Mice carrying a homozygous point mutation in <italic toggle="yes">Usp53</italic> were initially identified in a large-scale screen for novel recessive deafness traits.<xref ref-type="bibr" rid="bib48"><sup>48</sup></xref> Importantly, TJP2 deficiency in humans has also been linked to hearing impairment.<xref ref-type="bibr" rid="bib49"><sup>49</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib50"><sup>50</sup></xref></p></sec><sec id="sec2.1.5"><title>LSR deficiency</title><p id="p0090">Pathogenic mutations in the gene encoding lipolysis-stimulated lipoprotein receptor (LSR) have recently been associated with PFIC.<xref ref-type="bibr" rid="bib42"><sup>42</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib51"><sup>51</sup></xref> LSR is highly expressed in hepatocytes, binds apolipoprotein B/E-containing lipoproteins and plays a pivotal role in the formation of the tricellular tight junction complexes formed between three neighbouring cells.<xref ref-type="bibr" rid="bib52"><sup>52</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib53"><sup>53</sup></xref> Mice with deletion of Lsr are not viable and show liver hypoplasia at the time of death.<xref ref-type="bibr" rid="bib53"><sup>53</sup></xref> LSR deficiency in humans presents as low-GGT cholestasis and was associated with speech and developmental delay,<xref ref-type="bibr" rid="bib42"><sup>42</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib51"><sup>51</sup></xref> which may be attributed to the high expression of LSR in the blood-brain barrier and central nervous system.</p></sec><sec id="sec2.1.6"><title>MYO5B deficiency</title><p id="p0095">Mutations in the Myosin 5B (<italic toggle="yes">MYO5B</italic>) gene have been associated with microvillus inclusion disease, low-GGT intrahepatic cholestasis in the absence of intestinal symptoms, or a combination of both phenotypes.<xref ref-type="bibr" rid="bib54">[54]</xref>, <xref ref-type="bibr" rid="bib55">[55]</xref>, <xref ref-type="bibr" rid="bib56">[56]</xref>, <xref ref-type="bibr" rid="bib57">[57]</xref>, <xref ref-type="bibr" rid="bib58">[58]</xref> While biallelic PPTM in <italic toggle="yes">MYO5B</italic> predispose to microvillus inclusion disease, mutations with residual function often manifest as intrahepatic cholestasis without overt intestinal disease.<xref ref-type="bibr" rid="bib59"><sup>59</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib60"><sup>60</sup></xref> MYO5B plays a role in plasma membrane recycling, intracellular vesicular trafficking and cell polarisation in enterocytes and hepatocytes.<xref ref-type="bibr" rid="bib61"><sup>61</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib62"><sup>62</sup></xref> In hepatocytes, MYO5B interacts with RAB11A to promote canalicular trafficking of hepatobiliary transporters, such as BSEP, MDR3 and MRP2. Immunohistochemistry revealed subcanalicular, and in some cases additionally, reduced staining for BSEP and RAB11 as a potential mechanism of primary cholestasis.<xref ref-type="bibr" rid="bib54"><sup>54</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib55"><sup>55</sup></xref></p></sec><sec id="sec2.1.7"><title>SEMA7A deficiency</title><p id="p0100">Semaphorin7A (<italic toggle="yes">SEMA7A</italic>) also known as CD108 is a membrane-bound protein expressed in different epithelial cells, including hepatocytes, that has been linked to immune cell activation, pulmonary fibrosis and cancer progression.<xref ref-type="bibr" rid="bib63"><sup>63</sup></xref> A homozygous missense mutation was identified in a child with a PFIC phenotype and elevated serum BAs. Introducing the SEMA7A p.R148W mutation into a mouse model led to dose-dependent spontaneous elevation of serum BAs, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels, as well as steatosis development.<xref ref-type="bibr" rid="bib63"><sup>63</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib64"><sup>64</sup></xref> Mechanistically, increased phosphorylation of PKCδ/ε, as well as a reduction and intracellular retention of Bsep and Mrp2, was observed.<xref ref-type="bibr" rid="bib63"><sup>63</sup></xref> Moreover, SEMA7A interacts and activates integrin α<sub>5</sub>β<sub>1</sub>,<xref ref-type="bibr" rid="bib65"><sup>65</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib66"><sup>66</sup></xref> leading to insertion of Bsep into the canalicular membrane and promoting choleresis,<xref ref-type="bibr" rid="bib67"><sup>67</sup></xref> which may be an alternative explanation for SEMA7A-associated cholestasis. Canalicular morphology and localisation of canalicular transporters is disturbed in mice with β1 integrin deficiency.<xref ref-type="bibr" rid="bib68"><sup>68</sup></xref></p></sec><sec id="sec2.1.8"><title>ABCC12 deficiency</title><p id="p0105">Another ABC transporter more recently linked to intrahepatic cholestasis is MRP9, encoded by the <italic toggle="yes">ABCC12</italic> gene.<xref ref-type="bibr" rid="bib69"><sup>69</sup></xref> The substrates transported by MRP9 have not been elucidated. MRP9 is expressed in cholangiocytes and MRP9 deficiency is characterised by bile duct loss, but normal GGT cholestasis. The latter is surprising as deletion of <italic toggle="yes">Abcc12</italic> in zebrafish and mice resulted in increased cholangiocyte apoptosis, bile duct loss, elevated alkaline phosphatase (ALP) and liver fibrosis.<xref ref-type="bibr" rid="bib69"><sup>69</sup></xref></p></sec><sec id="sec2.1.9"><title>Cholestasis-associated genes affecting intracellular trafficking</title><p id="p0110"><italic toggle="yes">VPS33B, VIPAS39</italic> (encoding VIPAR), <italic toggle="yes">AP1S1</italic> and <italic toggle="yes">SCYL1</italic>, similarly to <italic toggle="yes">MYO5B</italic>, are associated with intracellular trafficking and recycling of endosomes.<xref ref-type="bibr" rid="bib70"><sup>70</sup></xref> Mutations in these genes have been linked to low-GGT primary cholestasis and additionally predispose individuals to rare multisystem cholestasis syndromes, such as arthrogryposis–renal dysfunction–cholestasis (<italic toggle="yes">VPS33B, VIPAS39</italic>),<xref ref-type="bibr" rid="bib71"><sup>71</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib72"><sup>72</sup></xref> MEDNIK (mental retardation, enteropathy, deafness, peripheral neuropathy, ichthyosis, keratoderma; <italic toggle="yes">AP1S1</italic>)<xref ref-type="bibr" rid="bib73"><sup>73</sup></xref> and CALFAN (with low-GGT cholestasis, acute liver failure, and neurodegeneration; <italic toggle="yes">SCYL1</italic>).<xref ref-type="bibr" rid="bib74"><sup>74</sup></xref> VPS33B deficiency leads to intracellular retention of BSEP and thus primary cholestasis.<xref ref-type="bibr" rid="bib75"><sup>75</sup></xref></p></sec></sec><sec id="sec2.2"><title>Genes associated with cholangiopathies and elevated GGT levels</title><p id="p0115">Mutations in genes associated with cholangiopathies include <italic toggle="yes">ABCB4</italic>, <italic toggle="yes">KIF12</italic>, <italic toggle="yes">ZFYVE19</italic>, <italic toggle="yes">CLDN1</italic>, <italic toggle="yes">DCDC2</italic>, <italic toggle="yes">PLEC1</italic>, <italic toggle="yes">UNC5A</italic>, <italic toggle="yes">JAG1</italic> and <italic toggle="yes">NOTCH2</italic>.<xref ref-type="bibr" rid="bib9"><sup>9</sup></xref> These are characterised by biliary damage and elevated GGT levels (<xref ref-type="table" rid="tbl2">Table 2</xref>).<table-wrap id="tbl2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Genes associated with cholangiopathies usually characterised by elevated GGT and ALP (modified from<xref ref-type="bibr" rid="bib9"><sup>9</sup></xref>).</p></caption><alt-text id="alttext0045">Table 2</alt-text><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Gene</th><th colspan="1" rowspan="1">Protein</th><th colspan="1" rowspan="1">Clinical manifestations</th><th colspan="1" rowspan="1">Extrahepatic manifestations</th></tr></thead><tbody><tr><td colspan="1" rowspan="1"><italic toggle="yes">ABCB4</italic></td><td colspan="1" rowspan="1">MDR3</td><td colspan="1" rowspan="1">PFIC, sclerosing cholangitis, biliary fibrosis, LPAC, gallstones, ICP, CCA, elevated LFTs</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">KIF12</italic></td><td colspan="1" rowspan="1">KIF12</td><td colspan="1" rowspan="1">PFIC, elevated LFTs</td><td colspan="1" rowspan="1">Normal renal function</td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">ZFYVE19</italic></td><td colspan="1" rowspan="1">ZFYVE19</td><td colspan="1" rowspan="1">Neonatal sclerosing cholangitis</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">CLDN1</italic></td><td colspan="1" rowspan="1">Claudin 1</td><td colspan="1" rowspan="1">Neonatal ichthyosis–sclerosing cholangitis (NISCH) syndrome, sclerosing cholangitis</td><td colspan="1" rowspan="1">Hypotrichosis, alopecia, ichthyosis</td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">DCDC2</italic></td><td colspan="1" rowspan="1">Doublecortin domain containing protein 2</td><td colspan="1" rowspan="1">Neonatal sclerosing cholangitis</td><td colspan="1" rowspan="1">Renal disease, nephronophthisis</td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">PLEC</italic></td><td colspan="1" rowspan="1">Plectin</td><td colspan="1" rowspan="1">PFIC</td><td colspan="1" rowspan="1">Plectinopathies, including epidermolysis, muscular dystrophy</td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">PSKH1</italic></td><td colspan="1" rowspan="1">Protein serine kinase H1</td><td colspan="1" rowspan="1">Cholangiopathy, biliary fibrosis</td><td colspan="1" rowspan="1">Glomerulopathy, developmental delay</td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">JAG1</italic></td><td colspan="1" rowspan="1">Jagged 1</td><td colspan="1" rowspan="1">Alagille syndrome</td><td colspan="1" rowspan="1">Features of Alagille</td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">NOTCH2</italic></td><td colspan="1" rowspan="1">NOTCH2</td><td colspan="1" rowspan="1">Alagille syndrome</td><td colspan="1" rowspan="1">Features of Alagille</td></tr></tbody></table><table-wrap-foot><fn><p>ALP, alkaline phosphatase; CCA, cholangiocarcinoma; GGT, gamma-glutamyltransferase; LFTs, liver function tests; LPAC, low phospholipid-associated cholelithiasis; PFIC, progressive familial intrahepatic cholestasis.</p></fn></table-wrap-foot></table-wrap></p><sec id="sec2.2.1"><title>MDR3 deficiency</title><p id="p0120"><italic toggle="yes">ABCB4</italic> encodes the multidrug-resistance protein 3 (MDR3), which is a phospholipid floppase essential for the extraction of phosphatidylcholine into bile.<xref ref-type="bibr" rid="bib76"><sup>76</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib77"><sup>77</sup></xref> Together with BAs, phosphatidylcholine forms mixed micelles increasing the solubility of cholesterol in bile and protecting the biliary epithelium from the detergent activity of bile acids.<xref ref-type="bibr" rid="bib78"><sup>78</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib79"><sup>79</sup></xref> Impaired MDR3 function leads to free BAs in bile, and subsequent cholangiocyte damage, resulting in progressive biliary fibrosis and/or PFIC with elevated GGT levels.<xref ref-type="bibr" rid="bib80"><sup>80</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib81"><sup>81</sup></xref> Furthermore, the reduced capacity to form mixed micelles increases the risk of gallstone disease and low phospholipid-associated cholelithiasis syndrome.<xref ref-type="bibr" rid="bib81">[81]</xref>, <xref ref-type="bibr" rid="bib82">[82]</xref>, <xref ref-type="bibr" rid="bib83">[83]</xref>, <xref ref-type="bibr" rid="bib84">[84]</xref>, <xref ref-type="bibr" rid="bib85">[85]</xref>, <xref ref-type="bibr" rid="bib86">[86]</xref>
<italic toggle="yes">Mdr2</italic>-deficient mice spontaneously develop gallstones, a progressive liver disease characterised by periductal fibrosis and biliary strictures, and hepatobiliary malignancy.<xref ref-type="bibr" rid="bib79"><sup>79</sup></xref> While patients carrying biallelic <italic toggle="yes">ABCB4</italic> PPTMs usually present early in life with PFIC, less severe mutations manifest in adults as intrahepatic cholestasis or pregnancy (ICP), elevated GGT, gallstone disease, biliary fibrosis and hepatobiliary malignancy.<xref ref-type="bibr" rid="bib7"><sup>7</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib80"><sup>80</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib81"><sup>81</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib86">[86]</xref>, <xref ref-type="bibr" rid="bib87">[87]</xref>, <xref ref-type="bibr" rid="bib88">[88]</xref>, <xref ref-type="bibr" rid="bib89">[89]</xref>, <xref ref-type="bibr" rid="bib90">[90]</xref> Compared to patients with biallelic PPTMs, the presence of at least one <italic toggle="yes">ABCB4</italic> missense mutation and biliary phospholipid levels greater than 6.9% of total biliary lipids was predictive of a response to ursodeoxycholic acid (UDCA) and prolonged native liver survival.<xref ref-type="bibr" rid="bib90"><sup>90</sup></xref></p></sec><sec id="sec2.2.2"><title>KIF12 deficiency</title><p id="p0125">Kinesin related protein 12 (KIF12) is putatively a microtubule-associated motor protein predicted to play a role in intracellular trafficking and cytoskeleton organisation.<xref ref-type="bibr" rid="bib91"><sup>91</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib92"><sup>92</sup></xref> Biallelic mutations in <italic toggle="yes">KIF12</italic> were identified in infants with high-GGT PFIC (cholangiopathy).<xref ref-type="bibr" rid="bib42"><sup>42</sup></xref> In comparison to serum BAs, GGT levels were severely elevated.<xref ref-type="bibr" rid="bib42"><sup>42</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib93"><sup>93</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib94"><sup>94</sup></xref> Immunohistochemistry of livers from patients with KIF12 deficiency revealed a reduced apical localisation of BSEP and MRP2 similar to MYO5B deficiency. However, the mechanisms leading to the marked GGT elevation and a more pronounced cholangiopathic presentation are unclear.</p></sec><sec id="sec2.2.3"><title>ZFYVE19 deficiency</title><p id="p0130">Mutations in the zinc finger FYVE-type containing 19 (<italic toggle="yes">ZFYVE19</italic>) gene have been described in patients with high-GGT PFIC characterised by biliary tract abnormalities and congenital fibrosing cholangiopathy.<xref ref-type="bibr" rid="bib95"><sup>95</sup></xref>
<italic toggle="yes">Zfyve19</italic>-deficient mice do not develop liver disease on regular chow diet; however, after exposure to α-naphthyl isothiocyanate, markers of liver injury were elevated in serum (ALT, ALP and BAs) and abnormal cholangiocyte polarity and portal fibrosis were observed on histology.<xref ref-type="bibr" rid="bib96"><sup>96</sup></xref> Impaired centrosome splitting and cell division was detected in isolated cells, which was most likely responsible for the increased cholangiocyte apoptosis.<xref ref-type="bibr" rid="bib96"><sup>96</sup></xref> Similarly, disruption of primary cilia structure and altered centriole number and localisation have been described in patient-derived fibroblasts.<xref ref-type="bibr" rid="bib97"><sup>97</sup></xref></p></sec><sec id="sec2.2.4"><title>Further genes associated with cholangiopathy development</title><p id="p0135">Ciliopathies presenting as sclerosing cholangitis together with different extrahepatic manifestations have been attributed to mutations in the genes encoding claudin 1 (<italic toggle="yes">CLDN1</italic>) and doublecortin domain containing protein 2 (<italic toggle="yes">DCDC2</italic>).<xref ref-type="bibr" rid="bib98">[98]</xref>, <xref ref-type="bibr" rid="bib99">[99]</xref>, <xref ref-type="bibr" rid="bib100">[100]</xref> Moreover, mutations in the <italic toggle="yes">PSKH1</italic> and <italic toggle="yes">PLEC</italic> genes may predispose to an early-onset cholangiopathy and cholestasis<xref ref-type="bibr" rid="bib101"><sup>101</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib102"><sup>102</sup></xref> and mutations in <italic toggle="yes">JAG1</italic> and <italic toggle="yes">NOTCH2</italic> underlie Alagille syndrome.<xref ref-type="bibr" rid="bib103"><sup>103</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib104"><sup>104</sup></xref></p></sec></sec></sec><sec id="sec3"><title>Clinical presentations associated with genetic cholestasis in adults</title><p id="p0140">The clinical presentation of adults carrying pathogenic mutations in the genes mentioned above is highly variable. In fact, even within one family different phenotypes have been reported in individuals carrying the same mutation.<xref ref-type="bibr" rid="bib7"><sup>7</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib8"><sup>8</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib105"><sup>105</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib106"><sup>106</sup></xref> Patients with biallelic PPTMs usually present early in life with PFIC. Biallelic variants with residual function and heterozygous variants tend to manifest as milder phenotypes. Patients may present with elevated liver enzymes, pruritus, episodic cholestasis, ICP, drug-induced liver injury, gallstones/low phospholipid-associated cholelithiasis syndrome or more severe late-onset PFIC, progressive liver disease and hepatobiliary malignancies, or combinations thereof.<xref ref-type="bibr" rid="bib7"><sup>7</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib8"><sup>8</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib105"><sup>105</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib107"><sup>107</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib108"><sup>108</sup></xref> For several genetic cholangiopathies, but especially for MDR3 deficiency, clinical presentation and features may resemble primary sclerosing cholangitis (PSC) or Caroli disease/syndrome, with dilatation of intrahepatic ducts on both magnetic resonance cholangiopancreatography and histology.<xref ref-type="bibr" rid="bib87"><sup>87</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib108">[108]</xref>, <xref ref-type="bibr" rid="bib109">[109]</xref>, <xref ref-type="bibr" rid="bib110">[110]</xref> Pruritus and fatigue are common symptoms not only of primary biliary cholangitis (PBC) but also of hereditary cholestasis; thus, some of these patients may be mislabelled as having anti-mitochondrial antibody/anti-nuclear antibody-negative (seronegative) PBC.<xref ref-type="bibr" rid="bib6"><sup>6</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib111"><sup>111</sup></xref></p></sec><sec id="sec4"><title>Diagnosis of genetic cholestasis in adults</title><p id="p0145">The large overlap in clinical presentation, imaging and sometimes even histological findings of more common liver diseases with hereditary primary cholestasis and cholangiopathies warrants a stepwise approach to diagnosis (<xref ref-type="fig" rid="fig3">Fig. 3</xref>). As a first step, low-GGT primary cholestasis, which is characterised by elevated ALT, AST, BAs, and often bilirubin, should be distinguished from high-GGT cholangiopathy. In both cases diagnostic workup for more common liver diseases should precede genetic analysis. Most patients will receive a diagnosis during this workup. Those patients who remain undiagnosed should undergo genetic testing and/or liver biopsy.<fig id="fig3" orientation="portrait" position="float"><label>Fig. 3</label><caption><p>Approach to adults with liver disease.</p><p>AIC, autoimmune cholestasis; AIH, autoimmune hepatitis; ALD, alcohol-related liver disease; BA, bile acid; ICP, intrahepatic cholestasis of pregnancy; MASLD, metabolic dysfunction-associated steatotic liver disease; MetALD, metabolic- and alcohol-associated steatotic liver disease; NGS, next-generation sequencing; PBC, primary biliary cholangitis; PSC, primary sclerosing cholangitis; SSC, secondary sclerosing cholangitis; MRCP, magnetic resonance cholangiopancreatography; WES, whole-exome sequencing; WGS, whole-genome sequencing.</p></caption><alt-text id="alttext0030">Fig. 3</alt-text><graphic orientation="portrait" position="float" xlink:href="gr3.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/></fig></p><p id="p0150">Reduced sequencing costs and the increased availability of clinical genomic testing, both commercially and through academic-affiliated laboratories, have made genomic analysis more accessible in clinical practice. Nevertheless, there remains an unmet need for increased education and awareness of adult-presenting genetic cholestatic liver diseases, particularly in non-tertiary academic medical centres. When a hepatologist suspects a genetic liver disease, they can opt to order a gene panel test, WES or even whole-genome sequencing.<xref ref-type="bibr" rid="bib112"><sup>112</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib113"><sup>113</sup></xref> Clinical geneticists search for rare genetic variants (typically with a frequency of less than 1% in the general population for recessive inheritance) in genes known to cause cholestasis and predict their impact on protein function. Given the ongoing identification of new liver disease-associated genes,<xref ref-type="bibr" rid="bib114"><sup>114</sup></xref> gene panels require regular updating to include newly discovered genes, whereas WES captures and sequences nearly all coding regions of approximately 20,000 human protein coding genes. WES workup usually includes a first analysis with a predefined virtual gene panel (similar to a next-generation sequencing panel) and, if the diagnosis remains unclear, can be extended to a more in-depth analysis of all coding regions. In addition, negative genetic testing does not fully exclude an underlying genetic condition. Re-analysis of WES data at later time points can cost-effectively increase the diagnostic yield (∼10-30% additional variants in disease-associated or candidate genes),<xref ref-type="bibr" rid="bib115"><sup>115</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib116"><sup>116</sup></xref> primarily through the identification of newly discovered genetic disorders. Hence, WES re-analysis is recommended for patients with unexplained cholestasis every 1 to 2 years, but at least every 3 years.<xref ref-type="bibr" rid="bib112"><sup>112</sup></xref> Gene panels and WES primarily identify variants in coding regions of the human genome. Studies are required to investigate the burden and spectrum of single nucleotide variants, indels and structural variations in non-coding regulatory regions that are not captured by gene panels or WES. Moreover, emerging evidence implicates somatic mutations in rare genetic liver diseases, such as in alpha-1-antitrypsin deficiency,<xref ref-type="bibr" rid="bib117"><sup>117</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib118"><sup>118</sup></xref> though their role in cholestatic disorders remains to be explored.</p><p id="p0155">A challenge with gene panel tests and/or WES in diagnosing and managing adult liver disease is the identification of genetic variants of unknown significance (VUS). This classification is based on criteria put forward by the ACMG (American College of Medical Genetics and Genomics). These criteria include information on the inheritance of the variant (monoallelic or bi-allelic), allelic frequency in the general population (allelic frequency in affected and healthy individuals), <italic toggle="yes">in silico</italic> computational predictive data and available (experimental) functional data for likely or definitive pathogenicity. As more data become available, VUS can be reclassified as either pathogenic or benign. In some cases, additional investigations of clinically accessible tissue or samples may allow for reclassification of VUS. Examples are testing of hepatic mRNA levels in a suspected splice variant or determining biliary BA or phospholipid levels in an <italic toggle="yes">ABCB11</italic> or <italic toggle="yes">ABCB4</italic> VUS. Patient-derived induced pluripotent stem-cell-derived hepatocytes may also enable further functional characterisation of a VUS; however, they are only available for a limited number of cases<xref ref-type="bibr" rid="bib40"><sup>40</sup></xref> (<xref ref-type="fig" rid="fig4">Fig. 4</xref>). The key question in interpreting genetic test results is whether the identified variants can fully or at least partly explain the patient’s clinical phenotype. To address this diagnostic challenge, a few centres have established multidisciplinary genome rounds, which integrate clinical and genetic information to achieve a definitive diagnosis. This approach relies on the expertise of adult and paediatric hepatologists, liver pathologists and clinical geneticists and has direct implications for optimising patient management, refining prognostic assessment and guiding family counselling.<xref ref-type="bibr" rid="bib119"><sup>119</sup></xref><fig id="fig4" orientation="portrait" position="float"><label>Fig. 4</label><caption><p>Factors to consider when evaluating the potential clinical relevance of a variant of unknown significance.</p><p>While the left boxes (light grey) are evaluated by the geneticist and underlie the classification as variants of unknown significance, the right column (light blue) contains factors that can be assessed by the clinician for further evaluation of a variant of unknown significance. MAF, minor allele frequency.</p></caption><alt-text id="alttext0035">Fig. 4</alt-text><graphic orientation="portrait" position="float" xlink:href="gr4.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/></fig></p><p id="p0160">A liver biopsy can support a role of the genetic abnormality in the clinical phenotype if lesions are compatible with the known histological effect of the protein deficiency. Histology results can provide insightful information to better understand the consequences of the genetic defects in the liver tissue in this heterogeneous group of patients. Although there is individual variability in the phenotypic expression at the tissue level among patients with the same variants, liver biopsy remains an effective tool to provide integrative information on clinical, genetic, and histological findings.<xref ref-type="bibr" rid="bib119"><sup>119</sup></xref></p></sec><sec id="sec5"><title>Pathology</title><p id="p0165">None of the lesions described in genetic cholestasis are specific to these diseases; therefore, the combination of clinical/biochemical/serological/radiological context is essential for correct diagnosis.<xref ref-type="bibr" rid="bib8"><sup>8</sup></xref> When a genetic abnormality is known, the role of liver biopsy is to support or refute the potentially harmful effect of the gene variant(s) based on currently available information. When the biopsy is performed before available genetic results there are some features that should raise concern and prompt genetic cholestasis testing. The EASL CPG for genetic cholestasis recommends that a liver biopsy should be considered when careful non-invasive evaluation remains inconclusive.<xref ref-type="bibr" rid="bib112"><sup>112</sup></xref></p><p id="p0170">In primary cholestasis, the injury will primarily affect hepatocytes, with abnormal/excessive accumulation of toxic bile components within the cell, which may be represented histologically by visualisation of bile pigment (so-called bilirubinostasis) in the hepatocyte cytoplasm and more typically within dilated canaliculi. This can be associated with cytopathic damage of hepatocytes, characterised by loss of the polygonal shape, swelling and clear appearance of the cytoplasm, changes in cell arrangement with cholestatic rosettes, and hepatocellular multinucleation. If these changes are not associated with significant portal or lobular inflammation the diagnosis of bland cholestasis is made. This histological pattern is typical for ICP and recurrent intrahepatic cholestasis. Bland cholestasis can be seen in other clinical settings such as septic conditions, ischaemia, and some paraneoplastic manifestations (<italic toggle="yes">e.g</italic>. Hodgkin’s lymphoma), although the latter cannot exclude an underlying genetic abnormality.</p><p id="p0175">Cholestatic hepatitis is defined by lobular bile stasis in association with a lobular hepatitis component. In this situation portal inflammation and bile duct injury may also be present. This pattern of injury is typical for drug-induced liver injury. It can be present in other aetiologies of hepatitis, such as viral or autoimmune hepatitis, but in these contexts the necroinflammatory injury component dominates the histological picture.</p><p id="p0180">Cholangiopathy in adult-onset genetic cholestasis may show overlapping features with PSC, or early-stage PBC when granulomas are absent. Normal biliary tree imaging and absence of typical serologic autoimmune markers would support a potential genetic cholestasis. Cases previously reported as small duct PSC or atypical forms of PBC (anti-mitochondrial antibody-negative, ductopenic PBC in young patients) may in fact represent phenotypic forms of PFIC. MDR3 deficiency is the most common genetic condition in adult patients with biopsy-proven cholangiopathy, while less commonly affected genes, such as <italic toggle="yes">KIF12</italic>, should also be considered. Liver biopsy in MDR3 deficiency (usually in a patient with dominant elevation of ALP and GGT with/without hypertransaminasemia) may reveal focal portal involvement and variable disease stages, ranging from subtle bile duct damage in a minority of portal tracts to established chronic biliary disease with portal fibrosis or cirrhosis. In early stages, the histopathologist should carefully examine every portal area for bile duct abnormalities, given the mild and focal bile duct changes (<italic toggle="yes">e.g.</italic> cholangiocyte disarray or focal cell loss, thickening of the bile duct basement membrane, periductal fibrosis, or focal bile duct loss) can easily be overlooked.<xref ref-type="bibr" rid="bib87"><sup>87</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib107"><sup>107</sup></xref> Features of chronic cholestasis, which can also be very focal, are extremely helpful in supporting the diagnosis of early or established chronic biliary disease. In addition to cholate stasis in periportal hepatocytes, the use of special stains and immunohistochemistry are invaluable histological tools to demonstrate periportal copper or copper-associated protein deposition or periportal hepatocellular cytokeratin 7 expression.<xref ref-type="bibr" rid="bib120"><sup>120</sup></xref></p><p id="p0185">Any biopsy with “biliary features”, either bile duct injury with or without bile duct loss, biliary proliferation, and/or identification of periportal copper-associated protein or aberrant hepatocellular expression of cytokeratin 7, independent of the degree of fibrosis observed, should prompt consideration of the possibility of an underlying genetic condition in patients with normal magnetic resonance cholangiopancreatography and absence of typical autoimmune serology. In the exceptional situation where cholesterol clefts or intrahepatic lithiasis are identified within the biopsied bile ducts, the most likely diagnosis is MDR3 deficiency.<xref ref-type="bibr" rid="bib121"><sup>121</sup></xref></p><p id="p0190">After a genetic or non-genetic diagnosis is reached, patients should be monitored for new symptoms and signs, as well as treatment response. If novel findings occur or the response to treatment is incomplete, consider potential additional or alternative causes including re-entering the patient into the diagnostic workup algorithm. Sometimes a re-analysis of the histopathology or genetic findings can reveal novel aspects underappreciated on the initial evaluation.<xref ref-type="bibr" rid="bib4"><sup>4</sup></xref> Furthermore, the adult-onset presentation of known paediatric cholestatic liver diseases has only recently been recognised; prospective data will provide insight into their natural history.</p></sec><sec id="sec6"><title>Treatment of genetic cholestasis in adults</title><p id="p0195">There have been no randomised controlled trials in adult-onset genetic cholestasis. The strongest evidence supporting treatment choices comes from paediatric trials, retrospective cohort studies and empirical treatment. Management of genetic cholestasis should best be thought of at several levels. The ideal treatment should target the underlying pathology, and in this respect a clear understanding of the pathophysiology in each patient is essential. If targeted treatment is not possible, treatment for cholestasis may be required, and finally treatment of the consequences of cholestasis may be necessary; this should include symptom control and nutritional support.</p><p id="p0200">Mutation- or gene-specific treatments are still pre-clinical for these diseases. In most cases it is likely that severe early-onset phenotypes will be treated in initial trials. However, inclusion of adult cohorts will be essential if therapy is to be made available to adult patients in the future. Targeted therapy, for now, consists of addressing the major components of the diseases, as discussed above. The retention of components of bile in hepatocytes, along with its consequences, is a feature common to nearly all these conditions. However, the potentially toxic milieu of bile may be modified in the case of the cholangiopathies.</p><p id="p0205">UDCA has been widely used in cholestatic diseases, genetic or otherwise. It is itself a BA and might even be harmful in severe cholestasis. However, there are suggestions that it can increase BSEP expression, which would be beneficial in many conditions.<xref ref-type="bibr" rid="bib122"><sup>122</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib123"><sup>123</sup></xref> The evidence of clinical benefit is missing. The only good evidence for the use of UDCA is in non-genetic cholangiopathies, such as PBC, and in MDR3 deficiency.<xref ref-type="bibr" rid="bib90"><sup>90</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib124">[124]</xref>, <xref ref-type="bibr" rid="bib125">[125]</xref>, <xref ref-type="bibr" rid="bib126">[126]</xref> In the latter, BA toxicity in bile is at the heart of the disease, and reducing the hydrophobicity of the BA pool is entirely logical. Retrospective data show that biochemical improvement, after the introduction of UDCA in MDR3 deficiency, improves outcomes.<xref ref-type="bibr" rid="bib90"><sup>90</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib126"><sup>126</sup></xref> The use of other hydrophilic BAs, such as norucholic acid, is logical, but unproven.</p><p id="p0210">Depletion of BA pool size, by interruption of the enterohepatic circulation of BAs or through inhibition of BA synthesis, is a logical intervention in most forms of cholestasis. One possible benefit might be a reduction of BA retention in the liver and a consequent reduction in liver damage and symptoms such as pruritus. The second benefit might be enrichment of the BA pool and enhancement of the effect of hydrophilic BA treatment. The latter is not yet proven. Depletion of the BA pool has been undertaken mechanically, via partial external biliary diversion or nasobiliary drainage.<xref ref-type="bibr" rid="bib17"><sup>17</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib112"><sup>112</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib127"><sup>127</sup></xref><sup>,</sup><xref ref-type="bibr" rid="bib128"><sup>128</sup></xref> Historically the only non-invasive option has been BA-binding resins. These have limited value, and suffer from reducing the availability of BAs in the small bowel, and from binding lipophilic dietary components, notably fat-soluble vitamins.<xref ref-type="bibr" rid="bib112"><sup>112</sup></xref> Recent paediatric studies have shown considerable efficacy from the use of inhibitors of ASBT (apical sodium dependent bile salt transporter), also known as IBAT (ileal bile acid transporter). Randomised controlled trials of both odevixibat and maralixibat in various types of PFIC have shown efficacy and tolerability.<xref ref-type="bibr" rid="bib129">[129]</xref>, <xref ref-type="bibr" rid="bib130">[130]</xref>, <xref ref-type="bibr" rid="bib131">[131]</xref>, <xref ref-type="bibr" rid="bib132">[132]</xref> These drugs are now licensed for the treatment of PFIC in many countries. The adult diseases discussed in this article are milder versions of the diseases studied in the pivotal trials. It is logical to think that these drugs will work in milder phenotypes.</p><p id="p0215">FXR agonists have not been systematically explored in genetic cholestasis to date. They may aid BA depletion, potentially in combination with other treatments. However, in cholestasis, there is already a high level of hepatocyte FXR activation from the accumulated BAs.</p><p id="p0220">Bezafibrate, which is approved for the treatment of dyslipidaemia, has been successfully used as second-line therapy in patients with PBC and an incomplete response to UDCA. Besides reduction in ALP levels, bezafibrate significantly reduced pruritus in patients with PBC and PSC.<xref ref-type="bibr" rid="bib133"><sup>133</sup></xref>
<xref ref-type="bibr" rid="bib134"><sup>134</sup></xref> Treatment of dyslipidaemia with bezafibrate in children with FIC1 deficiency alleviated pruritus in all three patients.<xref ref-type="bibr" rid="bib135"><sup>135</sup></xref> A reduction in pruritus in response to bezafibrate has also been observed in individual patients with BSEP deficiency (VK personal communication), but clinical trial data are lacking.</p><p id="p0225">Prior to the availability of targeted drugs, the mainstays of management for these conditions were focused on symptoms and the prevention of complications. Treatment of pruritus, as opposed to treatment of the underlying disease, remains unsatisfactory. In addition to UDCA, rifampicin, ondansetron, naltrexone and selective serotonin reuptake inhibitors have all been used. None have been subject to rigorous trials. Monitoring for fat-soluble vitamin deficiency, and supplementation where necessary, is essential. Nutritional support might also be needed.</p><p id="p0230">Monitoring for complications of chronic liver disease is essential in these conditions. Cholangiopathies, MDR3 deficiency in particular, have been strongly associated with the development of both hepatocellular carcinoma and cholangiocarcinoma. Indeed, hepatobiliary malignancy is the initial presentation in some cases.</p></sec><sec id="sec7"><title>Conclusions</title><p id="p0235">Genetic defects are increasingly recognised as causative or relevant contributing factors in adult cholestatic liver disease. The broad spectrum of clinical presentations poses a major challenge in reaching a diagnosis; therefore, a stepwise approach is suggested. Management of genetic cholestasis should target the underlying pathology whenever possible, should alleviate the consequences of cholestasis and should include symptom control.</p><p id="p0240">Lastly, given the insidious nature of some adult-onset genetic cholestatic liver diseases and the presence of disease in individuals who are only heterozygous for disease-causing mutations, we suggest screening heterozygous parents for liver disease at the time of their child’s diagnosis.</p></sec><sec id="sec8"><title>Abbreviations</title><p id="p0245">ABCB4/11, ABC transporter B4/11; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ATP8B1, ATPase phospholipid transporting 8B1; BA, bile acid; BSEP, bile salt export pump; FIC1, familial intrahepatic cholestasis 1; FXR, farnesoid X receptor; GGT, gamma-glutamyltransferase; ICP, intrahepatic cholestasis of pregnancy; KIF12, kinesin related protein 12; LPAC, low phospholipid-associated cholelithiasis; LSR, lipolysis-stimulated lipoprotein receptor; MYO5B, myosin 5B; NR1H4, nuclear receptor 1H4; PBC, primary biliary cholangitis; PFIC, progressive familial intrahepatic cholestasis; PPTM, predicted protein truncating mutation; PSC, primary sclerosing cholangitis; SEMA7A, semaphorin 7A; TJP2, tight junction protein 2; UDCA, ursodeoxycholic acid; USP53, ubiquitin carboxyl-terminal hydrolase 53; VUS, variant of unknown significance; WES, whole-exome sequencing; ZFYVE19, zinc finger FYVE-type containing 19.</p></sec><sec id="sec10"><title>Financial support</title><p id="p0255">SV is supported by <funding-source id="gs1">NIDDK</funding-source>, R01 DK131033, VK is supported by <funding-source id="gs2">BMBF</funding-source> through <funding-source id="gs3">HiChol</funding-source> (01GM1904A and 01GM2204A).</p></sec><sec id="sec9"><title>Authors’ contributions</title><p id="p0250">VK designed the manuscript and created the figures. RT, RM, SV and VK created the diagnostic algorithm. VK, RT, RM, SV wrote the manuscript and all approved the final version.</p></sec><sec id="coi0010" sec-type="COI-statement"><title>Conflict of interest</title><p id="p0260">No author received funding for this publication. RJT has consulted for Mirum, Ipsen, Alnylam, Spruce Bio, Glycomine, Rectify, and Generation Bio. He has received speaker’s honoraria from Mirum and Ipsen. He has stock/options in Rectify, Generation Bio and Integra. VK received honoraria for speaker’s corner from Falk, Mirum, Ipsen, GSK, Gilead and participated in advisory boards by Mirum, Ipsen, Falk and GSK. SV served as consultant for Mirum and Ipsen and received research grant support from Moderna.</p><p id="p0265">Please refer to the accompanying ICMJE disclosure forms for further details.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation id="sref1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Popper</surname><given-names>H.</given-names></name><name name-style="western"><surname>Schaffner</surname><given-names>F.</given-names></name></person-group><article-title>Pathophysiology of cholestasis</article-title><source>Hum Pathol</source><volume>1</volume><year>1970</year><fpage>1</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">4940286</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/s0046-8177(70)80002-8</pub-id></element-citation></ref><ref id="bib2"><label>2</label><element-citation id="sref2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bull</surname><given-names>L.N.</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>R.J.</given-names></name></person-group><article-title>Progressive familial intrahepatic cholestasis</article-title><source>Clin Liver Dis</source><volume>22</volume><year>2018</year><fpage>657</fpage><lpage>669</lpage><pub-id pub-id-type="pmid">30266155</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.cld.2018.06.003</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation id="sref3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vilarinho</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mistry</surname><given-names>P.K.</given-names></name></person-group><article-title>Exome sequencing in clinical hepatology</article-title><source>Hepatology</source><volume>70</volume><year>2019</year><fpage>2185</fpage><lpage>2192</lpage><pub-id pub-id-type="pmid">31222768</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1002/hep.30826</pub-id><pub-id pub-id-type="pmcid">PMC6885087</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation id="sref4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hakim</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>DeLisle</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Clinical utility of genomic analysis in adults with idiopathic liver disease</article-title><source>J Hepatol</source><volume>70</volume><year>2019</year><fpage>1214</fpage><lpage>1221</lpage><pub-id pub-id-type="pmid">31000363</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.jhep.2019.01.036</pub-id><pub-id pub-id-type="pmcid">PMC6526061</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation id="sref5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hakim</surname><given-names>A.</given-names></name><name name-style="western"><surname>Konkwo</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Advancing diagnosis and management of liver disease in adults through exome sequencing</article-title><source>EBioMedicine</source><volume>95</volume><year>2023</year><object-id pub-id-type="publisher-id">104747</object-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.ebiom.2023.104747</pub-id><pub-id pub-id-type="pmcid">PMC10433007</pub-id><pub-id pub-id-type="pmid">37566928</pub-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation id="sref6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vitale</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gitto</surname><given-names>S.</given-names></name><name name-style="western"><surname>Raimondi</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Cryptogenic cholestasis in young and adults: ATP8B1, ABCB11, ABCB4, and TJP2 gene variants analysis by high-throughput sequencing</article-title><source>J Gastroenterol</source><volume>53</volume><year>2018</year><fpage>945</fpage><lpage>958</lpage><pub-id pub-id-type="pmid">29238877</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1007/s00535-017-1423-1</pub-id></element-citation></ref><ref id="bib7"><label>7</label><element-citation id="sref7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dröge</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bonus</surname><given-names>M.</given-names></name><name name-style="western"><surname>Baumann</surname><given-names>U.</given-names></name><etal/></person-group><article-title>Sequencing of FIC1, BSEP and MDR3 in a large cohort of patients with cholestasis revealed a high number of different genetic variants</article-title><source>J Hepatol</source><volume>67</volume><year>2017</year><fpage>1253</fpage><lpage>1264</lpage><pub-id pub-id-type="pmid">28733223</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.jhep.2017.07.004</pub-id></element-citation></ref><ref id="bib8"><label>8</label><element-citation id="sref8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nayagam</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Foskett</surname><given-names>P.</given-names></name><name name-style="western"><surname>Strautnieks</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Clinical phenotype of adult-onset liver disease in patients with variants in ABCB4, ABCB11, and ATP8B1</article-title><source>Hepatol Commun</source><volume>6</volume><year>2022</year><fpage>2654</fpage><lpage>2664</lpage><pub-id pub-id-type="pmid">35894240</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1002/hep4.2051</pub-id><pub-id pub-id-type="pmcid">PMC9512461</pub-id></element-citation></ref><ref id="bib9"><label>9</label><element-citation id="sref9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ibrahim</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Kamath</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Loomes</surname><given-names>K.M.</given-names></name><etal/></person-group><article-title>Cholestatic liver diseases of genetic etiology: advances and controversies</article-title><source>Hepatology</source><volume>75</volume><year>2022</year><fpage>1627</fpage><lpage>1646</lpage><pub-id pub-id-type="pmid">35229330</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1002/hep.32437</pub-id></element-citation></ref><ref id="bib10"><label>10</label><element-citation id="sref10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heubi</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Setchell</surname><given-names>K.D.R.</given-names></name><name name-style="western"><surname>Bove</surname><given-names>K.E.</given-names></name></person-group><article-title>Inborn errors of bile acid metabolism</article-title><source>Clin Liver Dis</source><volume>22</volume><year>2018</year><fpage>671</fpage><lpage>687</lpage><pub-id pub-id-type="pmid">30266156</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.cld.2018.06.006</pub-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation id="sref11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Strautnieks</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Bull</surname><given-names>L.N.</given-names></name><name name-style="western"><surname>Knisely</surname><given-names>A.S.</given-names></name><etal/></person-group><article-title>A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis</article-title><source>Nat Genet</source><volume>20</volume><year>1998</year><fpage>233</fpage><lpage>238</lpage><pub-id pub-id-type="pmid">9806540</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1038/3034</pub-id></element-citation></ref><ref id="bib12"><label>12</label><element-citation id="sref12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Noe</surname><given-names>J.</given-names></name><name name-style="western"><surname>Stieger</surname><given-names>B.</given-names></name><name name-style="western"><surname>Meier</surname><given-names>P.J.</given-names></name></person-group><article-title>Functional expression of the canalicular bile salt export pump of human liver</article-title><source>Gastroenterology</source><volume>123</volume><year>2002</year><fpage>1659</fpage><lpage>1666</lpage><pub-id pub-id-type="pmid">12404240</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1053/gast.2002.36587</pub-id></element-citation></ref><ref id="bib13"><label>13</label><element-citation id="sref13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sinal</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Tohkin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Miyata</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis</article-title><source>Cell</source><volume>102</volume><year>2000</year><fpage>731</fpage><lpage>744</lpage><pub-id pub-id-type="pmid">11030617</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/s0092-8674(00)00062-3</pub-id></element-citation></ref><ref id="bib14"><label>14</label><element-citation id="sref14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schuetz</surname><given-names>E.G.</given-names></name><name name-style="western"><surname>Strom</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yasuda</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Disrupted bile acid homeostasis reveals an unexpected interaction among nuclear hormone receptors, transporters, and cytochrome P450</article-title><source>J Biol Chem</source><volume>276</volume><year>2001</year><fpage>39411</fpage><lpage>39418</lpage><pub-id pub-id-type="pmid">11509573</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1074/jbc.M106340200</pub-id></element-citation></ref><ref id="bib15"><label>15</label><element-citation id="sref15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Strautnieks</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Byrne</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Pawlikowska</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Severe bile salt export pump deficiency: 82 different ABCB11 mutations in 109 families</article-title><source>Gastroenterology</source><volume>134</volume><year>2008</year><fpage>1203</fpage><lpage>1214</lpage><pub-id pub-id-type="pmid">18395098</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1053/j.gastro.2008.01.038</pub-id></element-citation></ref><ref id="bib16"><label>16</label><element-citation id="sref16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gomez-Ospina</surname><given-names>N.</given-names></name><name name-style="western"><surname>Potter</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Mutations in the nuclear bile acid receptor FXR cause progressive familial intrahepatic cholestasis</article-title><source>Nat Commun</source><volume>7</volume><year>2016</year><object-id pub-id-type="publisher-id">10713</object-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1038/ncomms10713</pub-id><pub-id pub-id-type="pmcid">PMC4759630</pub-id><pub-id pub-id-type="pmid">26888176</pub-id></element-citation></ref><ref id="bib17"><label>17</label><element-citation id="sref17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Wessel</surname><given-names>D.B.E.</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Gonzales</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Genotype correlates with the natural history of severe bile salt export pump deficiency</article-title><source>J Hepatol</source><volume>73</volume><year>2020</year><fpage>84</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">32087350</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.jhep.2020.02.007</pub-id></element-citation></ref><ref id="bib18"><label>18</label><element-citation id="sref18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Felzen</surname><given-names>A.</given-names></name><name name-style="western"><surname>van Wessel</surname><given-names>D.B.E.</given-names></name><name name-style="western"><surname>Gonzales</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Genotype-phenotype relationships of truncating mutations, p.E297G and p.D482G in bile salt export pump deficiency</article-title><source>JHEP Rep</source><volume>5</volume><year>2023</year><object-id pub-id-type="publisher-id">100626</object-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.jhepr.2022.100626</pub-id><pub-id pub-id-type="pmcid">PMC9852554</pub-id><pub-id pub-id-type="pmid">36687469</pub-id></element-citation></ref><ref id="bib19"><label>19</label><element-citation id="sref19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hayashi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Takada</surname><given-names>T.</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Two common PFIC2 mutations are associated with the impaired membrane trafficking of BSEP/ABCB11</article-title><source>Hepatology</source><volume>41</volume><year>2005</year><fpage>916</fpage><lpage>924</lpage><pub-id pub-id-type="pmid">15791618</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1002/hep.20627</pub-id></element-citation></ref><ref id="bib20"><label>20</label><element-citation id="sref20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Mil</surname><given-names>S.W.</given-names></name><name name-style="western"><surname>van der Woerd</surname><given-names>W.L.</given-names></name><name name-style="western"><surname>van der Brugge</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Benign recurrent intrahepatic cholestasis type 2 is caused by mutations in ABCB11</article-title><source>Gastroenterology</source><volume>127</volume><year>2004</year><fpage>379</fpage><lpage>384</lpage><pub-id pub-id-type="pmid">15300568</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1053/j.gastro.2004.04.065</pub-id></element-citation></ref><ref id="bib21"><label>21</label><element-citation id="sref21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Ooteghem</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Klomp</surname><given-names>L.W.</given-names></name><name name-style="western"><surname>van Berge-Henegouwen</surname><given-names>G.P.</given-names></name><etal/></person-group><article-title>Benign recurrent intrahepatic cholestasis progressing to progressive familial intrahepatic cholestasis: low GGT cholestasis is a clinical continuum</article-title><source>J Hepatol</source><volume>36</volume><year>2002</year><fpage>439</fpage><lpage>443</lpage><pub-id pub-id-type="pmid">11867191</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/s0168-8278(01)00299-9</pub-id></element-citation></ref><ref id="bib22"><label>22</label><element-citation id="sref22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Mil</surname><given-names>S.W.</given-names></name><name name-style="western"><surname>Milona</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dixon</surname><given-names>P.H.</given-names></name><etal/></person-group><article-title>Functional variants of the central bile acid sensor FXR identified in intrahepatic cholestasis of pregnancy</article-title><source>Gastroenterology</source><volume>133</volume><year>2007</year><fpage>507</fpage><lpage>516</lpage><pub-id pub-id-type="pmid">17681172</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1053/j.gastro.2007.05.015</pub-id></element-citation></ref><ref id="bib23"><label>23</label><element-citation id="sref23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dixon</surname><given-names>P.H.</given-names></name><name name-style="western"><surname>van Mil</surname><given-names>S.W.</given-names></name><name name-style="western"><surname>Chambers</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Contribution of variant alleles of ABCB11 to susceptibility to intrahepatic cholestasis of pregnancy</article-title><source>Gut</source><volume>58</volume><year>2009</year><fpage>537</fpage><lpage>544</lpage><pub-id pub-id-type="pmid">18987030</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1136/gut.2008.159541</pub-id></element-citation></ref><ref id="bib24"><label>24</label><element-citation id="sref24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Byrne</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Strautnieks</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Ihrke</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Missense mutations and single nucleotide polymorphisms in ABCB11 impair bile salt export pump processing and function or disrupt pre-messenger RNA splicing</article-title><source>Hepatology</source><volume>49</volume><year>2009</year><fpage>553</fpage><lpage>567</lpage><pub-id pub-id-type="pmid">19101985</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1002/hep.22683</pub-id></element-citation></ref><ref id="bib25"><label>25</label><element-citation id="sref25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meier</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Pauli-Magnus</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zanger</surname><given-names>U.M.</given-names></name><etal/></person-group><article-title>Interindividual variability of canalicular ATP-binding-cassette (ABC)-transporter expression in human liver</article-title><source>Hepatology</source><volume>44</volume><year>2006</year><fpage>62</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">16799996</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1002/hep.21214</pub-id></element-citation></ref><ref id="bib26"><label>26</label><element-citation id="sref26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muhlfeld</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kubitz</surname><given-names>R.</given-names></name><name name-style="western"><surname>Dransfeld</surname><given-names>O.</given-names></name><etal/></person-group><article-title>Taurine supplementation induces multidrug resistance protein 2 and bile salt export pump expression in rats and prevents endotoxin-induced cholestasis</article-title><source>Arch Biochem Biophys</source><volume>413</volume><year>2003</year><fpage>32</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">12706339</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/s0003-9861(03)00098-5</pub-id></element-citation></ref><ref id="bib27"><label>27</label><element-citation id="sref27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vallejo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Briz</surname><given-names>O.</given-names></name><name name-style="western"><surname>Serrano</surname><given-names>M.A.</given-names></name><etal/></person-group><article-title>Potential role of trans-inhibition of the bile salt export pump by progesterone metabolites in the etiopathogenesis of intrahepatic cholestasis of pregnancy</article-title><source>J Hepatol</source><volume>44</volume><year>2006</year><fpage>1150</fpage><lpage>1157</lpage><pub-id pub-id-type="pmid">16458994</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.jhep.2005.09.017</pub-id></element-citation></ref><ref id="bib28"><label>28</label><element-citation id="sref28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stieger</surname><given-names>B.</given-names></name><name name-style="western"><surname>Fattinger</surname><given-names>K.</given-names></name><name name-style="western"><surname>Madon</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver</article-title><source>Gastroenterology</source><volume>118</volume><year>2000</year><fpage>422</fpage><lpage>430</lpage><pub-id pub-id-type="pmid">10648470</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/s0016-5085(00)70224-1</pub-id></element-citation></ref><ref id="bib29"><label>29</label><element-citation id="sref29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stieger</surname><given-names>B.</given-names></name></person-group><article-title>Role of the bile salt export pump, BSEP, in acquired forms of cholestasis</article-title><source>Drug Metab Rev</source><volume>42</volume><year>2010</year><fpage>437</fpage><lpage>445</lpage><pub-id pub-id-type="pmid">20028269</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.3109/03602530903492004</pub-id></element-citation></ref><ref id="bib30"><label>30</label><element-citation id="sref30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meier</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zodan</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lang</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Increased susceptibility for intrahepatic cholestasis of pregnancy and contraceptive-induced cholestasis in carriers of the 1331T&gt;C polymorphism in the bile salt export pump</article-title><source>World J Gastroenterol</source><volume>14</volume><year>2008</year><fpage>38</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">18176959</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.3748/wjg.14.38</pub-id><pub-id pub-id-type="pmcid">PMC2673389</pub-id></element-citation></ref><ref id="bib31"><label>31</label><element-citation id="sref31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paulusma</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>de Waart</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Kunne</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Activity of the bile salt export pump (ABCB11) is critically dependent on canalicular membrane cholesterol content</article-title><source>J Biol Chem</source><volume>284</volume><year>2009</year><fpage>9947</fpage><lpage>9954</lpage><pub-id pub-id-type="pmid">19228692</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1074/jbc.M808667200</pub-id><pub-id pub-id-type="pmcid">PMC2665118</pub-id></element-citation></ref><ref id="bib32"><label>32</label><element-citation id="sref32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paulusma</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Groen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kunne</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Atp8b1 deficiency in mice reduces resistance of the canalicular membrane to hydrophobic bile salts and impairs bile salt transport</article-title><source>Hepatology</source><volume>44</volume><year>2006</year><fpage>195</fpage><lpage>204</lpage><pub-id pub-id-type="pmid">16799980</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1002/hep.21212</pub-id></element-citation></ref><ref id="bib33"><label>33</label><element-citation id="sref33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bull</surname><given-names>L.N.</given-names></name><name name-style="western"><surname>van Eijk</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Pawlikowska</surname><given-names>L.</given-names></name><etal/></person-group><article-title>A gene encoding a P-type ATPase mutated in two forms of hereditary cholestasis</article-title><source>Nat Genet</source><volume>18</volume><year>1998</year><fpage>219</fpage><lpage>224</lpage><pub-id pub-id-type="pmid">9500542</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1038/ng0398-219</pub-id></element-citation></ref><ref id="bib34"><label>34</label><element-citation id="sref34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van der Mark</surname><given-names>V.A.</given-names></name><name name-style="western"><surname>de Jonge</surname><given-names>H.R.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>J.C.</given-names></name><etal/></person-group><article-title>The phospholipid flippase ATP8B1 mediates apical localization of the cystic fibrosis transmembrane regulator</article-title><source>Biochim Biophys Acta</source><volume>1863</volume><year>2016</year><fpage>2280</fpage><lpage>2288</lpage><pub-id pub-id-type="pmid">27301931</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.bbamcr.2016.06.005</pub-id></element-citation></ref><ref id="bib35"><label>35</label><element-citation id="sref35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Wessel</surname><given-names>D.B.E.</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Gonzales</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Impact of genotype, serum bile acids, and surgical biliary diversion on native liver survival in FIC1 deficiency</article-title><source>Hepatology</source><volume>74</volume><year>2021</year><fpage>892</fpage><lpage>906</lpage><pub-id pub-id-type="pmid">33666275</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1002/hep.31787</pub-id><pub-id pub-id-type="pmcid">PMC8456904</pub-id></element-citation></ref><ref id="bib36"><label>36</label><element-citation id="sref36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sambrotta</surname><given-names>M.</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>R.J.</given-names></name></person-group><article-title>Mutations in TJP2, encoding zona occludens 2, and liver disease</article-title><source>Tissue Barriers</source><volume>3</volume><year>2015</year><object-id pub-id-type="publisher-id">e1026537</object-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1080/21688370.2015.1026537</pub-id><pub-id pub-id-type="pmcid">PMC4574888</pub-id><pub-id pub-id-type="pmid">26451340</pub-id></element-citation></ref><ref id="bib37"><label>37</label><element-citation id="sref37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carlton</surname><given-names>V.E.</given-names></name><name name-style="western"><surname>Harris</surname><given-names>B.Z.</given-names></name><name name-style="western"><surname>Puffenberger</surname><given-names>E.G.</given-names></name><etal/></person-group><article-title>Complex inheritance of familial hypercholanemia with associated mutations in TJP2 and BAAT</article-title><source>Nat Genet</source><volume>34</volume><year>2003</year><fpage>91</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">12704386</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1038/ng1147</pub-id></element-citation></ref><ref id="bib38"><label>38</label><element-citation id="sref38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sambrotta</surname><given-names>M.</given-names></name><name name-style="western"><surname>Strautnieks</surname><given-names>S.</given-names></name><name name-style="western"><surname>Papouli</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Mutations in TJP2 cause progressive cholestatic liver disease</article-title><source>Nat Genet</source><volume>46</volume><year>2014</year><fpage>326</fpage><lpage>328</lpage><pub-id pub-id-type="pmid">24614073</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1038/ng.2918</pub-id><pub-id pub-id-type="pmcid">PMC4061468</pub-id></element-citation></ref><ref id="bib39"><label>39</label><element-citation id="sref39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kausalya</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Van Hul</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Protective functions of ZO-2/Tjp2 expressed in hepatocytes and cholangiocytes against liver injury and cholestasis</article-title><source>Gastroenterology</source><volume>160</volume><year>2021</year><fpage>2103</fpage><lpage>2118</lpage><pub-id pub-id-type="pmid">33465371</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1053/j.gastro.2021.01.027</pub-id></element-citation></ref><ref id="bib40"><label>40</label><element-citation id="sref40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>C.Z.</given-names></name><name name-style="western"><surname>Ogawa</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ng</surname><given-names>S.S.</given-names></name><etal/></person-group><article-title>Human iPSC-derived hepatocyte system models cholestasis with tight junction protein 2 deficiency</article-title><source>JHEP Rep</source><volume>4</volume><year>2022</year><object-id pub-id-type="publisher-id">100446</object-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.jhepr.2022.100446</pub-id><pub-id pub-id-type="pmcid">PMC8904612</pub-id><pub-id pub-id-type="pmid">35284810</pub-id></element-citation></ref><ref id="bib41"><label>41</label><element-citation id="sref41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lal</surname><given-names>B.B.</given-names></name><name name-style="western"><surname>Alam</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sibal</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Genotype correlates with clinical course and outcome of children with tight junction protein 2 (TJP2) deficiency-related cholestasis</article-title><source>Hepatology</source><volume>80</volume><year>2024</year><fpage>511</fpage><lpage>526</lpage><pub-id pub-id-type="pmid">38447037</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1097/HEP.0000000000000828</pub-id></element-citation></ref><ref id="bib42"><label>42</label><element-citation id="sref42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maddirevula</surname><given-names>S.</given-names></name><name name-style="western"><surname>Alhebbi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Alqahtani</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Identification of novel loci for pediatric cholestatic liver disease defined by KIF12, PPM1F, USP53, LSR, and WDR83OS pathogenic variants</article-title><source>Genet Med</source><volume>21</volume><year>2019</year><fpage>1164</fpage><lpage>1172</lpage><pub-id pub-id-type="pmid">30250217</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1038/s41436-018-0288-x</pub-id></element-citation></ref><ref id="bib43"><label>43</label><element-citation id="sref43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>J.Y.</given-names></name><etal/></person-group><article-title>Low-GGT intrahepatic cholestasis associated with biallelic USP53 variants: clinical, histological and ultrastructural characterization</article-title><source>Liver Int</source><volume>40</volume><year>2020</year><fpage>1142</fpage><lpage>1150</lpage><pub-id pub-id-type="pmid">32124521</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1111/liv.14422</pub-id></element-citation></ref><ref id="bib44"><label>44</label><element-citation id="sref44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Quesada</surname><given-names>V.</given-names></name><name name-style="western"><surname>Diaz-Perales</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gutierrez-Fernandez</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Cloning and enzymatic analysis of 22 novel human ubiquitin-specific proteases</article-title><source>Biochem Biophys Res Commun</source><volume>314</volume><year>2004</year><fpage>54</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">14715245</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.bbrc.2003.12.050</pub-id></element-citation></ref><ref id="bib45"><label>45</label><element-citation id="sref45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ding</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>Y.L.</given-names></name><etal/></person-group><article-title>Loss of hepatocyte Usp53 protects mice from a form of xenobiotic-induced liver injury</article-title><source>Biochim Biophys Acta Mol Basis Dis</source><volume>1871</volume><year>2025</year><object-id pub-id-type="publisher-id">167624</object-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.bbadis.2024.167624</pub-id><pub-id pub-id-type="pmid">39705897</pub-id></element-citation></ref><ref id="bib46"><label>46</label><element-citation id="sref46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shah</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sanford</surname><given-names>U.R.</given-names></name><name name-style="western"><surname>Vargas</surname><given-names>J.C.</given-names></name><etal/></person-group><article-title>Strain background modifies phenotypes in the ATP8B1-deficient mouse</article-title><source>PLoS One</source><volume>5</volume><year>2010</year><object-id pub-id-type="publisher-id">e8984</object-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1371/journal.pone.0008984</pub-id><pub-id pub-id-type="pmcid">PMC2813882</pub-id><pub-id pub-id-type="pmid">20126555</pub-id></element-citation></ref><ref id="bib47"><label>47</label><element-citation id="sref47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lam</surname><given-names>P.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Severe cholestasis induced by cholic acid feeding in knockout mice of sister of P-glycoprotein</article-title><source>Hepatology</source><volume>38</volume><year>2003</year><fpage>1489</fpage><lpage>1499</lpage><pub-id pub-id-type="pmid">14647060</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.hep.2003.09.037</pub-id></element-citation></ref><ref id="bib48"><label>48</label><element-citation id="sref48" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kazmierczak</surname><given-names>M.</given-names></name><name name-style="western"><surname>Harris</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Kazmierczak</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Progressive hearing loss in mice carrying a mutation in Usp53</article-title><source>J Neurosci</source><volume>35</volume><year>2015</year><fpage>15582</fpage><lpage>15598</lpage><pub-id pub-id-type="pmid">26609154</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1523/JNEUROSCI.1965-15.2015</pub-id><pub-id pub-id-type="pmcid">PMC4659823</pub-id></element-citation></ref><ref id="bib49"><label>49</label><element-citation id="sref49" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zou</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mei</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Whole-exome sequencing identifies rare pathogenic and candidate variants in sporadic Chinese Han deaf patients</article-title><source>Clin Genet</source><volume>97</volume><year>2020</year><fpage>352</fpage><lpage>356</lpage><pub-id pub-id-type="pmid">31486067</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1111/cge.13638</pub-id></element-citation></ref><ref id="bib50"><label>50</label><element-citation id="sref50" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahmadmehrabi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hui</surname><given-names>D.</given-names></name><etal/></person-group><article-title>A genome-first approach to rare variants in dominant postlingual hearing loss genes in a large adult population</article-title><source>Otolaryngol Head Neck Surg</source><volume>166</volume><year>2022</year><fpage>746</fpage><lpage>752</lpage><pub-id pub-id-type="pmid">34281439</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1177/01945998211029544</pub-id></element-citation></ref><ref id="bib51"><label>51</label><element-citation id="sref51" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uehara</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yamada</surname><given-names>M.</given-names></name><name name-style="western"><surname>Umetsu</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Biallelic mutations in the LSR gene cause a novel type of infantile intrahepatic cholestasis</article-title><source>J Pediatr</source><volume>221</volume><year>2020</year><fpage>251</fpage><lpage>254</lpage><pub-id pub-id-type="pmid">32303357</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.jpeds.2020.01.064</pub-id></element-citation></ref><ref id="bib52"><label>52</label><element-citation id="sref52" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Masuda</surname><given-names>S.</given-names></name><name name-style="western"><surname>Oda</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sasaki</surname><given-names>H.</given-names></name><etal/></person-group><article-title>LSR defines cell corners for tricellular tight junction formation in epithelial cells</article-title><source>J Cell Sci</source><volume>124</volume><year>2011</year><fpage>548</fpage><lpage>555</lpage><pub-id pub-id-type="pmid">21245199</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1242/jcs.072058</pub-id></element-citation></ref><ref id="bib53"><label>53</label><element-citation id="sref53" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mesli</surname><given-names>S.</given-names></name><name name-style="western"><surname>Javorschi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Berard</surname><given-names>A.M.</given-names></name><etal/></person-group><article-title>Distribution of the lipolysis stimulated receptor in adult and embryonic murine tissues and lethality of LSR-/- embryos at 12.5 to 14.5 days of gestation</article-title><source>Eur J Biochem</source><volume>271</volume><year>2004</year><fpage>3103</fpage><lpage>3114</lpage><pub-id pub-id-type="pmid">15265030</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1111/j.1432-1033.2004.04223.x</pub-id></element-citation></ref><ref id="bib54"><label>54</label><element-citation id="sref54" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gonzales</surname><given-names>E.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Davit-Spraul</surname><given-names>A.</given-names></name><etal/></person-group><article-title>MYO5B mutations cause cholestasis with normal serum gamma-glutamyl transferase activity in children without microvillous inclusion disease</article-title><source>Hepatology</source><volume>65</volume><year>2017</year><fpage>164</fpage><lpage>173</lpage><pub-id pub-id-type="pmid">27532546</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1002/hep.28779</pub-id></element-citation></ref><ref id="bib55"><label>55</label><element-citation id="sref55" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qiu</surname><given-names>Y.L.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>J.Y.</given-names></name><etal/></person-group><article-title>Defects in myosin VB are associated with a spectrum of previously undiagnosed low gamma-glutamyltransferase cholestasis</article-title><source>Hepatology</source><volume>65</volume><year>2017</year><fpage>1655</fpage><lpage>1669</lpage><pub-id pub-id-type="pmid">28027573</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1002/hep.29020</pub-id><pub-id pub-id-type="pmcid">PMC5413810</pub-id></element-citation></ref><ref id="bib56"><label>56</label><element-citation id="sref56" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muller</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hess</surname><given-names>M.W.</given-names></name><name name-style="western"><surname>Schiefermeier</surname><given-names>N.</given-names></name><etal/></person-group><article-title>MYO5B mutations cause microvillus inclusion disease and disrupt epithelial cell polarity</article-title><source>Nat Genet</source><volume>40</volume><year>2008</year><fpage>1163</fpage><lpage>1165</lpage><pub-id pub-id-type="pmid">18724368</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1038/ng.225</pub-id></element-citation></ref><ref id="bib57"><label>57</label><element-citation id="sref57" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ruemmele</surname><given-names>F.M.</given-names></name><name name-style="western"><surname>Muller</surname><given-names>T.</given-names></name><name name-style="western"><surname>Schiefermeier</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Loss-of-function of MYO5B is the main cause of microvillus inclusion disease: 15 novel mutations and a CaCo-2 RNAi cell model</article-title><source>Hum Mutat</source><volume>31</volume><year>2010</year><fpage>544</fpage><lpage>551</lpage><pub-id pub-id-type="pmid">20186687</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1002/humu.21224</pub-id></element-citation></ref><ref id="bib58"><label>58</label><element-citation id="sref58" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Girard</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lacaille</surname><given-names>F.</given-names></name><name name-style="western"><surname>Verkarre</surname><given-names>V.</given-names></name><etal/></person-group><article-title>MYO5B and bile salt export pump contribute to cholestatic liver disorder in microvillous inclusion disease</article-title><source>Hepatology</source><volume>60</volume><year>2014</year><fpage>301</fpage><lpage>310</lpage><pub-id pub-id-type="pmid">24375397</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1002/hep.26974</pub-id></element-citation></ref><ref id="bib59"><label>59</label><element-citation id="sref59" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aldrian</surname><given-names>D.</given-names></name><name name-style="western"><surname>Vogel</surname><given-names>G.F.</given-names></name><name name-style="western"><surname>Frey</surname><given-names>T.K.</given-names></name><etal/></person-group><article-title>Congenital diarrhea and cholestatic liver disease: phenotypic spectrum associated with MYO5B mutations</article-title><source>J Clin Med</source><volume>10</volume><year>2021</year><pub-id assigning-authority="pmc" pub-id-type="doi">10.3390/jcm10030481</pub-id><pub-id pub-id-type="pmcid">PMC7865828</pub-id><pub-id pub-id-type="pmid">33525641</pub-id></element-citation></ref><ref id="bib60"><label>60</label><element-citation id="sref60" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>Y.L.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>H.M.</given-names></name><etal/></person-group><article-title>MYO5B-associated diseases: novel liver-related variants and genotype-phenotype correlation</article-title><source>Liver Int</source><volume>42</volume><year>2022</year><fpage>402</fpage><lpage>411</lpage><pub-id pub-id-type="pmid">34811877</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1111/liv.15104</pub-id></element-citation></ref><ref id="bib61"><label>61</label><element-citation id="sref61" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Knowles</surname><given-names>B.C.</given-names></name><name name-style="western"><surname>Roland</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Krishnan</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Myosin Vb uncoupling from RAB8A and RAB11A elicits microvillus inclusion disease</article-title><source>J Clin Invest</source><volume>124</volume><year>2014</year><fpage>2947</fpage><lpage>2962</lpage><pub-id pub-id-type="pmid">24892806</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1172/JCI71651</pub-id><pub-id pub-id-type="pmcid">PMC4071383</pub-id></element-citation></ref><ref id="bib62"><label>62</label><element-citation id="sref62" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lapierre</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hales</surname><given-names>C.M.</given-names></name><etal/></person-group><article-title>Myosin vb is associated with plasma membrane recycling systems</article-title><source>Mol Biol Cell</source><volume>12</volume><year>2001</year><fpage>1843</fpage><lpage>1857</lpage><pub-id pub-id-type="pmid">11408590</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1091/mbc.12.6.1843</pub-id><pub-id pub-id-type="pmcid">PMC37346</pub-id></element-citation></ref><ref id="bib63"><label>63</label><element-citation id="sref63" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pan</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Qu</surname><given-names>J.</given-names></name><etal/></person-group><article-title>A homozygous R148W mutation in Semaphorin 7A causes progressive familial intrahepatic cholestasis</article-title><source>EMBO Mol Med</source><volume>13</volume><year>2021</year><object-id pub-id-type="publisher-id">e14563</object-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.15252/emmm.202114563</pub-id><pub-id pub-id-type="pmcid">PMC8573601</pub-id><pub-id pub-id-type="pmid">34585848</pub-id></element-citation></ref><ref id="bib64"><label>64</label><element-citation id="sref64" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>N.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>J.</given-names></name><etal/></person-group><article-title>SEMA7AR148W mutation promotes lipid accumulation and NAFLD progression via increased localization on the hepatocyte surface</article-title><source>JCI Insight</source><volume>7</volume><year>2022</year><pub-id assigning-authority="pmc" pub-id-type="doi">10.1172/jci.insight.154113</pub-id><pub-id pub-id-type="pmcid">PMC9462498</pub-id><pub-id pub-id-type="pmid">35938531</pub-id></element-citation></ref><ref id="bib65"><label>65</label><element-citation id="sref65" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Yeh</surname><given-names>C.R.</given-names></name><etal/></person-group><article-title>SEMA7a primes integrin alpha5beta1 engagement instructing fibroblast mechanotransduction, phenotype and transcriptional programming</article-title><source>Matrix Biol</source><volume>121</volume><year>2023</year><fpage>179</fpage><lpage>193</lpage><pub-id pub-id-type="pmid">37422024</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.matbio.2023.06.006</pub-id></element-citation></ref><ref id="bib66"><label>66</label><element-citation id="sref66" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>W.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>Q.</given-names></name><etal/></person-group><article-title>Semaphorin 7A interacts with nuclear factor NF-kappa-B p105 via integrin beta1 and mediates inflammation</article-title><source>Cell Commun Signal</source><volume>21</volume><year>2023</year><fpage>24</fpage><pub-id pub-id-type="pmid">36717921</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1186/s12964-022-01024-w</pub-id><pub-id pub-id-type="pmcid">PMC9885601</pub-id></element-citation></ref><ref id="bib67"><label>67</label><element-citation id="sref67" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gohlke</surname><given-names>H.</given-names></name><name name-style="western"><surname>Schmitz</surname><given-names>B.</given-names></name><name name-style="western"><surname>Sommerfeld</surname><given-names>A.</given-names></name><etal/></person-group><article-title>alpha5 beta1-integrins are sensors for tauroursodeoxycholic acid in hepatocytes</article-title><source>Hepatology</source><volume>57</volume><year>2013</year><fpage>1117</fpage><lpage>1129</lpage><pub-id pub-id-type="pmid">22865233</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1002/hep.25992</pub-id></element-citation></ref><ref id="bib68"><label>68</label><element-citation id="sref68" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Masuzaki</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ray</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Roland</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Integrin beta1 establishes liver microstructure and modulates transforming growth factor beta during liver development and regeneration</article-title><source>Am J Pathol</source><volume>191</volume><year>2021</year><fpage>309</fpage><lpage>319</lpage><pub-id pub-id-type="pmid">33159885</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.ajpath.2020.10.011</pub-id><pub-id pub-id-type="pmcid">PMC7888191</pub-id></element-citation></ref><ref id="bib69"><label>69</label><element-citation id="sref69" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pham</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Kudira</surname><given-names>R.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Deleterious variants in ABCC12 are detected in idiopathic chronic cholestasis and cause intrahepatic bile duct loss in model organisms</article-title><source>Gastroenterology</source><volume>161</volume><year>2021</year><fpage>287</fpage><lpage>300 e216</lpage><pub-id pub-id-type="pmid">33771553</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1053/j.gastro.2021.03.026</pub-id><pub-id pub-id-type="pmcid">PMC8238842</pub-id></element-citation></ref><ref id="bib70"><label>70</label><element-citation id="sref70" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y.</given-names></name><name name-style="western"><surname>van</surname><given-names>I.S.C.D.</given-names></name></person-group><article-title>A link between intrahepatic cholestasis and genetic variations in intracellular trafficking regulators</article-title><source>Biology (Basel)</source><volume>10</volume><year>2021</year><pub-id assigning-authority="pmc" pub-id-type="doi">10.3390/biology10020119</pub-id><pub-id pub-id-type="pmcid">PMC7914782</pub-id><pub-id pub-id-type="pmid">33557414</pub-id></element-citation></ref><ref id="bib71"><label>71</label><element-citation id="sref71" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gissen</surname><given-names>P.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Morgan</surname><given-names>N.V.</given-names></name><etal/></person-group><article-title>Mutations in VPS33B, encoding a regulator of SNARE-dependent membrane fusion, cause arthrogryposis-renal dysfunction-cholestasis (ARC) syndrome</article-title><source>Nat Genet</source><volume>36</volume><year>2004</year><fpage>400</fpage><lpage>404</lpage><pub-id pub-id-type="pmid">15052268</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1038/ng1325</pub-id></element-citation></ref><ref id="bib72"><label>72</label><element-citation id="sref72" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cullinane</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Straatman-Iwanowska</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zaucker</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Mutations in VIPAR cause an arthrogryposis, renal dysfunction and cholestasis syndrome phenotype with defects in epithelial polarization</article-title><source>Nat Genet</source><volume>42</volume><year>2010</year><fpage>303</fpage><lpage>312</lpage><pub-id pub-id-type="pmid">20190753</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1038/ng.538</pub-id><pub-id pub-id-type="pmcid">PMC5308204</pub-id></element-citation></ref><ref id="bib73"><label>73</label><element-citation id="sref73" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martinelli</surname><given-names>D.</given-names></name><name name-style="western"><surname>Travaglini</surname><given-names>L.</given-names></name><name name-style="western"><surname>Drouin</surname><given-names>C.A.</given-names></name><etal/></person-group><article-title>MEDNIK syndrome: a novel defect of copper metabolism treatable by zinc acetate therapy</article-title><source>Brain</source><volume>136</volume><year>2013</year><fpage>872</fpage><lpage>881</lpage><pub-id pub-id-type="pmid">23423674</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1093/brain/awt012</pub-id></element-citation></ref><ref id="bib74"><label>74</label><element-citation id="sref74" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lenz</surname><given-names>D.</given-names></name><name name-style="western"><surname>McClean</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kansu</surname><given-names>A.</given-names></name><etal/></person-group><article-title>SCYL1 variants cause a syndrome with low gamma-glutamyl-transferase cholestasis, acute liver failure, and neurodegeneration (CALFAN)</article-title><source>Genet Med</source><volume>20</volume><year>2018</year><fpage>1255</fpage><lpage>1265</lpage><pub-id pub-id-type="pmid">29419818</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1038/gim.2017.260</pub-id><pub-id pub-id-type="pmcid">PMC5989927</pub-id></element-citation></ref><ref id="bib75"><label>75</label><element-citation id="sref75" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hanley</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dhar</surname><given-names>D.K.</given-names></name><name name-style="western"><surname>Mazzacuva</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Vps33b is crucial for structural and functional hepatocyte polarity</article-title><source>J Hepatol</source><volume>66</volume><year>2017</year><fpage>1001</fpage><lpage>1011</lpage><pub-id pub-id-type="pmid">28082148</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.jhep.2017.01.001</pub-id><pub-id pub-id-type="pmcid">PMC5387182</pub-id></element-citation></ref><ref id="bib76"><label>76</label><element-citation id="sref76" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prescher</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bonus</surname><given-names>M.</given-names></name><name name-style="western"><surname>Stindt</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Evidence for a credit-card-swipe mechanism in the human PC floppase ABCB4</article-title><source>Structure</source><volume>29</volume><year>2021</year><fpage>1144</fpage><lpage>1155 e1145</lpage><pub-id pub-id-type="pmid">34107287</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.str.2021.05.013</pub-id></element-citation></ref><ref id="bib77"><label>77</label><element-citation id="sref77" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smit</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Schinkel</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Oude Elferink</surname><given-names>R.P.</given-names></name><etal/></person-group><article-title>Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease</article-title><source>Cell</source><volume>75</volume><year>1993</year><fpage>451</fpage><lpage>462</lpage><pub-id pub-id-type="pmid">8106172</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/0092-8674(93)90380-9</pub-id></element-citation></ref><ref id="bib78"><label>78</label><element-citation id="sref78" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Puglielli</surname><given-names>L.</given-names></name><name name-style="western"><surname>Amigo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Arrese</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Protective role of biliary cholesterol and phospholipid lamellae against bile acid-induced cell damage</article-title><source>Gastroenterology</source><volume>107</volume><year>1994</year><fpage>244</fpage><lpage>254</lpage><pub-id pub-id-type="pmid">8020668</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/0016-5085(94)90083-3</pub-id></element-citation></ref><ref id="bib79"><label>79</label><element-citation id="sref79" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mauad</surname><given-names>T.H.</given-names></name><name name-style="western"><surname>van Nieuwkerk</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Dingemans</surname><given-names>K.P.</given-names></name><etal/></person-group><article-title>Mice with homozygous disruption of the mdr2 P-glycoprotein gene. A novel animal model for studies of nonsuppurative inflammatory cholangitis and hepatocarcinogenesis</article-title><source>Am J Pathol</source><volume>145</volume><year>1994</year><fpage>1237</fpage><lpage>1245</lpage><pub-id pub-id-type="pmid">7977654</pub-id><pub-id pub-id-type="pmcid">PMC1887434</pub-id></element-citation></ref><ref id="bib80"><label>80</label><element-citation id="sref80" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Vree</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Jacquemin</surname><given-names>E.</given-names></name><name name-style="western"><surname>Sturm</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis</article-title><source>Proc Natl Acad Sci U S A</source><volume>95</volume><year>1998</year><fpage>282</fpage><lpage>287</lpage><pub-id pub-id-type="pmid">9419367</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1073/pnas.95.1.282</pub-id><pub-id pub-id-type="pmcid">PMC18201</pub-id></element-citation></ref><ref id="bib81"><label>81</label><element-citation id="sref81" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gudbjartsson</surname><given-names>D.F.</given-names></name><name name-style="western"><surname>Helgason</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gudjonsson</surname><given-names>S.A.</given-names></name><etal/></person-group><article-title>Large-scale whole-genome sequencing of the Icelandic population</article-title><source>Nat Genet</source><volume>47</volume><year>2015</year><fpage>435</fpage><lpage>444</lpage><pub-id pub-id-type="pmid">25807286</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1038/ng.3247</pub-id></element-citation></ref><ref id="bib82"><label>82</label><element-citation id="sref82" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pasmant</surname><given-names>E.</given-names></name><name name-style="western"><surname>Goussard</surname><given-names>P.</given-names></name><name name-style="western"><surname>Baranes</surname><given-names>L.</given-names></name><etal/></person-group><article-title>First description of ABCB4 gene deletions in familial low phospholipid-associated cholelithiasis and oral contraceptives-induced cholestasis</article-title><source>Eur J Hum Genet</source><volume>20</volume><year>2012</year><fpage>277</fpage><lpage>282</lpage><pub-id pub-id-type="pmid">21989363</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1038/ejhg.2011.186</pub-id><pub-id pub-id-type="pmcid">PMC3283179</pub-id></element-citation></ref><ref id="bib83"><label>83</label><element-citation id="sref83" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lammert</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D.Q.</given-names></name><name name-style="western"><surname>Hillebrandt</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Spontaneous cholecysto- and hepatolithiasis in Mdr2-/- mice: a model for low phospholipid-associated cholelithiasis</article-title><source>Hepatology</source><volume>39</volume><year>2004</year><fpage>117</fpage><lpage>128</lpage><pub-id pub-id-type="pmid">14752830</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1002/hep.20022</pub-id></element-citation></ref><ref id="bib84"><label>84</label><element-citation id="sref84" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosmorduc</surname><given-names>O.</given-names></name><name name-style="western"><surname>Hermelin</surname><given-names>B.</given-names></name><name name-style="western"><surname>Poupon</surname><given-names>R.</given-names></name></person-group><article-title>MDR3 gene defect in adults with symptomatic intrahepatic and gallbladder cholesterol cholelithiasis</article-title><source>Gastroenterology</source><volume>120</volume><year>2001</year><fpage>1459</fpage><lpage>1467</lpage><pub-id pub-id-type="pmid">11313316</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1053/gast.2001.23947</pub-id></element-citation></ref><ref id="bib85"><label>85</label><element-citation id="sref85" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosmorduc</surname><given-names>O.</given-names></name><name name-style="western"><surname>Poupon</surname><given-names>R.</given-names></name></person-group><article-title>Low phospholipid associated cholelithiasis: association with mutation in the MDR3/ABCB4 gene</article-title><source>Orphanet J Rare Dis</source><volume>2</volume><year>2007</year><fpage>29</fpage><pub-id pub-id-type="pmid">17562004</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1186/1750-1172-2-29</pub-id><pub-id pub-id-type="pmcid">PMC1910597</pub-id></element-citation></ref><ref id="bib86"><label>86</label><element-citation id="sref86" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dong</surname><given-names>C.</given-names></name><name name-style="western"><surname>Condat</surname><given-names>B.</given-names></name><name name-style="western"><surname>Picon-Coste</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Low-phospholipid-associated cholelithiasis syndrome: prevalence, clinical features, and comorbidities</article-title><source>JHEP Rep</source><volume>3</volume><year>2021</year><object-id pub-id-type="publisher-id">100201</object-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.jhepr.2020.100201</pub-id><pub-id pub-id-type="pmcid">PMC7848766</pub-id><pub-id pub-id-type="pmid">33554096</pub-id></element-citation></ref><ref id="bib87"><label>87</label><element-citation id="sref87" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Vries</surname><given-names>E.</given-names></name><name name-style="western"><surname>Mazzetti</surname><given-names>M.</given-names></name><name name-style="western"><surname>Takkenberg</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Carriers of ABCB4 gene variants show a mild clinical course, but impaired quality of life and limited risk for cholangiocarcinoma</article-title><source>Liver Int</source><volume>40</volume><year>2020</year><fpage>3042</fpage><lpage>3050</lpage><pub-id pub-id-type="pmid">32893960</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1111/liv.14662</pub-id></element-citation></ref><ref id="bib88"><label>88</label><element-citation id="sref88" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jacquemin</surname><given-names>E.</given-names></name><name name-style="western"><surname>Cresteil</surname><given-names>D.</given-names></name><name name-style="western"><surname>Manouvrier</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Heterozygous non-sense mutation of the MDR3 gene in familial intrahepatic cholestasis of pregnancy</article-title><source>Lancet</source><volume>353</volume><year>1999</year><fpage>210</fpage><lpage>211</lpage><pub-id pub-id-type="pmid">9923886</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/S0140-6736(05)77221-4</pub-id></element-citation></ref><ref id="bib89"><label>89</label><element-citation id="sref89" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jacquemin</surname><given-names>E.</given-names></name><name name-style="western"><surname>De Vree</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Cresteil</surname><given-names>D.</given-names></name><etal/></person-group><article-title>The wide spectrum of multidrug resistance 3 deficiency: from neonatal cholestasis to cirrhosis of adulthood</article-title><source>Gastroenterology</source><volume>120</volume><year>2001</year><fpage>1448</fpage><lpage>1458</lpage><pub-id pub-id-type="pmid">11313315</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1053/gast.2001.23984</pub-id></element-citation></ref><ref id="bib90"><label>90</label><element-citation id="sref90" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gonzales</surname><given-names>E.</given-names></name><name name-style="western"><surname>Gardin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Almes</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Outcomes of 38 patients with PFIC3: impact of genotype and of response to ursodeoxycholic acid therapy</article-title><source>JHEP Rep</source><volume>5</volume><year>2023</year><object-id pub-id-type="publisher-id">100844</object-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.jhepr.2023.100844</pub-id><pub-id pub-id-type="pmcid">PMC10494458</pub-id><pub-id pub-id-type="pmid">37701337</pub-id></element-citation></ref><ref id="bib91"><label>91</label><element-citation id="sref91" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miki</surname><given-names>H.</given-names></name><name name-style="western"><surname>Setou</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kaneshiro</surname><given-names>K.</given-names></name><etal/></person-group><article-title>All kinesin superfamily protein, KIF, genes in mouse and human</article-title><source>Proc Natl Acad Sci U S A</source><volume>98</volume><year>2001</year><fpage>7004</fpage><lpage>7011</lpage><pub-id pub-id-type="pmid">11416179</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1073/pnas.111145398</pub-id><pub-id pub-id-type="pmcid">PMC34614</pub-id></element-citation></ref><ref id="bib92"><label>92</label><element-citation id="sref92" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hirokawa</surname><given-names>N.</given-names></name><name name-style="western"><surname>Noda</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tanaka</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Kinesin superfamily motor proteins and intracellular transport</article-title><source>Nat Rev Mol Cell Biol</source><volume>10</volume><year>2009</year><fpage>682</fpage><lpage>696</lpage><pub-id pub-id-type="pmid">19773780</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1038/nrm2774</pub-id></element-citation></ref><ref id="bib93"><label>93</label><element-citation id="sref93" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stalke</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sgodda</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cantz</surname><given-names>T.</given-names></name><etal/></person-group><article-title>KIF12 variants and disturbed hepatocyte polarity in children with a phenotypic spectrum of cholestatic liver disease</article-title><source>J Pediatr</source><volume>240</volume><year>2022</year><fpage>284</fpage><lpage>291 e289</lpage><pub-id pub-id-type="pmid">34555379</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.jpeds.2021.09.019</pub-id></element-citation></ref><ref id="bib94"><label>94</label><element-citation id="sref94" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Unlusoy</surname><given-names>Aksu A.</given-names></name><name name-style="western"><surname>Das</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Nelson-Williams</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Recessive mutations in KIF12 cause high gamma-glutamyltransferase cholestasis</article-title><source>Hepatol Commun</source><volume>3</volume><year>2019</year><fpage>471</fpage><lpage>477</lpage><pub-id pub-id-type="pmid">30976738</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1002/hep4.1320</pub-id><pub-id pub-id-type="pmcid">PMC6442693</pub-id></element-citation></ref><ref id="bib95"><label>95</label><element-citation id="sref95" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luan</surname><given-names>W.</given-names></name><name name-style="western"><surname>Hao</surname><given-names>C.Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.Q.</given-names></name><etal/></person-group><article-title>Biallelic loss-of-function ZFYVE19 mutations are associated with congenital hepatic fibrosis, sclerosing cholangiopathy and high-GGT cholestasis</article-title><source>J Med Genet</source><volume>58</volume><year>2021</year><fpage>514</fpage><lpage>525</lpage><pub-id pub-id-type="pmid">32737136</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1136/jmedgenet-2019-106706</pub-id></element-citation></ref><ref id="bib96"><label>96</label><element-citation id="sref96" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.N.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>R.X.</given-names></name><etal/></person-group><article-title>ZFYVE19 deficiency: a ciliopathy involving failure of cell division, with cell death</article-title><source>J Med Genet</source><volume>61</volume><year>2024</year><fpage>750</fpage><lpage>758</lpage><pub-id pub-id-type="pmid">38816193</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1136/jmg-2023-109779</pub-id><pub-id pub-id-type="pmcid">PMC11287636</pub-id></element-citation></ref><ref id="bib97"><label>97</label><element-citation id="sref97" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mandato</surname><given-names>C.</given-names></name><name name-style="western"><surname>Siano</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Nazzaro</surname><given-names>L.</given-names></name><etal/></person-group><article-title>A ZFYVE19 gene mutation associated with neonatal cholestasis and cilia dysfunction: case report with a novel pathogenic variant</article-title><source>Orphanet J Rare Dis</source><volume>16</volume><year>2021</year><fpage>179</fpage><pub-id pub-id-type="pmid">33853651</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1186/s13023-021-01775-8</pub-id><pub-id pub-id-type="pmcid">PMC8048179</pub-id></element-citation></ref><ref id="bib98"><label>98</label><element-citation id="sref98" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Girard</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bizet</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Lachaux</surname><given-names>A.</given-names></name><etal/></person-group><article-title>DCDC2 mutations cause neonatal sclerosing cholangitis</article-title><source>Hum Mutat</source><volume>37</volume><year>2016</year><fpage>1025</fpage><lpage>1029</lpage><pub-id pub-id-type="pmid">27319779</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1002/humu.23031</pub-id></element-citation></ref><ref id="bib99"><label>99</label><element-citation id="sref99" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grammatikopoulos</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sambrotta</surname><given-names>M.</given-names></name><name name-style="western"><surname>Strautnieks</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Mutations in DCDC2 (doublecortin domain containing protein 2) in neonatal sclerosing cholangitis</article-title><source>J Hepatol</source><volume>65</volume><year>2016</year><fpage>1179</fpage><lpage>1187</lpage><pub-id pub-id-type="pmid">27469900</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.jhep.2016.07.017</pub-id><pub-id pub-id-type="pmcid">PMC5116266</pub-id></element-citation></ref><ref id="bib100"><label>100</label><element-citation id="sref100" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hadj-Rabia</surname><given-names>S.</given-names></name><name name-style="western"><surname>Baala</surname><given-names>L.</given-names></name><name name-style="western"><surname>Vabres</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Claudin-1 gene mutations in neonatal sclerosing cholangitis associated with ichthyosis: a tight junction disease</article-title><source>Gastroenterology</source><volume>127</volume><year>2004</year><fpage>1386</fpage><lpage>1390</lpage><pub-id pub-id-type="pmid">15521008</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1053/j.gastro.2004.07.022</pub-id></element-citation></ref><ref id="bib101"><label>101</label><element-citation id="sref101" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.L.</given-names></name><etal/></person-group><article-title>Plectin mutations in progressive familial intrahepatic cholestasis</article-title><source>Hepatology</source><volume>70</volume><year>2019</year><fpage>2221</fpage><lpage>2224</lpage><pub-id pub-id-type="pmid">31269534</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1002/hep.30841</pub-id></element-citation></ref><ref id="bib102"><label>102</label><element-citation id="sref102" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maddirevula</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shagrani</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ji</surname><given-names>A.R.</given-names></name><etal/></person-group><article-title>Large-scale genomic investigation of pediatric cholestasis reveals a novel hepatorenal ciliopathy caused by PSKH1 mutations</article-title><source>Genet Med</source><volume>26</volume><year>2024</year><object-id pub-id-type="publisher-id">101231</object-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.gim.2024.101231</pub-id><pub-id pub-id-type="pmid">39132680</pub-id></element-citation></ref><ref id="bib103"><label>103</label><element-citation id="sref103" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ayoub</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Bakhsh</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Vandriel</surname><given-names>S.M.</given-names></name><etal/></person-group><article-title>Management of adults with Alagille syndrome</article-title><source>Hepatol Int</source><volume>17</volume><year>2023</year><fpage>1098</fpage><lpage>1112</lpage><pub-id pub-id-type="pmid">37584849</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1007/s12072-023-10578-x</pub-id><pub-id pub-id-type="pmcid">PMC10522532</pub-id></element-citation></ref><ref id="bib104"><label>104</label><element-citation id="sref104" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ayoub</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Kamath</surname><given-names>B.M.</given-names></name></person-group><article-title>Alagille syndrome: current understanding of pathogenesis, and challenges in diagnosis and management</article-title><source>Clin Liver Dis</source><volume>26</volume><year>2022</year><fpage>355</fpage><lpage>370</lpage><pub-id pub-id-type="pmid">35868679</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.cld.2022.03.002</pub-id></element-citation></ref><ref id="bib105"><label>105</label><element-citation id="sref105" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sinha</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bhuva</surname><given-names>M.</given-names></name><name name-style="western"><surname>Grant</surname><given-names>C.</given-names></name><etal/></person-group><article-title>ABCB4 mutations in adults cause a spectrum cholestatic disorder histologically distinct from other biliary disease</article-title><source>Dig Dis Sci</source><volume>67</volume><year>2022</year><fpage>5551</fpage><lpage>5561</lpage><pub-id pub-id-type="pmid">35288833</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1007/s10620-022-07416-9</pub-id></element-citation></ref><ref id="bib106"><label>106</label><element-citation id="sref106" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gotthardt</surname><given-names>D.</given-names></name><name name-style="western"><surname>Runz</surname><given-names>H.</given-names></name><name name-style="western"><surname>Keitel</surname><given-names>V.</given-names></name><etal/></person-group><article-title>A mutation in the canalicular phospholipid transporter gene, ABCB4, is associated with cholestasis, ductopenia, and cirrhosis in adults</article-title><source>Hepatology</source><volume>48</volume><year>2008</year><fpage>1157</fpage><lpage>1166</lpage><pub-id pub-id-type="pmid">18781607</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1002/hep.22485</pub-id></element-citation></ref><ref id="bib107"><label>107</label><element-citation id="sref107" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stattermayer</surname><given-names>A.F.</given-names></name><name name-style="western"><surname>Halilbasic</surname><given-names>E.</given-names></name><name name-style="western"><surname>Wrba</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Variants in ABCB4 (MDR3) across the spectrum of cholestatic liver diseases in adults</article-title><source>J Hepatol</source><volume>73</volume><year>2020</year><fpage>651</fpage><lpage>663</lpage><pub-id pub-id-type="pmid">32376413</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.jhep.2020.04.036</pub-id></element-citation></ref><ref id="bib108"><label>108</label><element-citation id="sref108" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Avena</surname><given-names>A.</given-names></name><name name-style="western"><surname>Puggelli</surname><given-names>S.</given-names></name><name name-style="western"><surname>Morris</surname><given-names>M.</given-names></name><etal/></person-group><article-title>ABCB4 variants in adult patients with cholestatic disease are frequent and underdiagnosed</article-title><source>Dig Liver Dis</source><volume>53</volume><year>2021</year><fpage>329</fpage><lpage>344</lpage><pub-id pub-id-type="pmid">33390354</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.dld.2020.12.003</pub-id></element-citation></ref><ref id="bib109"><label>109</label><element-citation id="sref109" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Biyoukar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Corpechot</surname><given-names>C.</given-names></name><name name-style="western"><surname>El Mouhadi</surname><given-names>S.</given-names></name><etal/></person-group><article-title>A BCB4 variant is associated with hepatobiliary MR abnormalities in people with low-phospholipid-associated cholelithiasis syndrome</article-title><source>JHEP Rep</source><volume>4</volume><year>2022</year><object-id pub-id-type="publisher-id">100590</object-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.jhepr.2022.100590</pub-id><pub-id pub-id-type="pmcid">PMC9582794</pub-id><pub-id pub-id-type="pmid">36277956</pub-id></element-citation></ref><ref id="bib110"><label>110</label><element-citation id="sref110" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Poupon</surname><given-names>R.</given-names></name><name name-style="western"><surname>Arrive</surname><given-names>L.</given-names></name><name name-style="western"><surname>Rosmorduc</surname><given-names>O.</given-names></name></person-group><article-title>The cholangiographic features of severe forms of ABCB4/MDR3 deficiency-associated cholangiopathy in adults</article-title><source>Gastroenterol Clin Biol</source><volume>34</volume><year>2010</year><fpage>380</fpage><lpage>387</lpage><pub-id pub-id-type="pmid">20537830</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.gcb.2010.04.011</pub-id></element-citation></ref><ref id="bib111"><label>111</label><element-citation id="sref111" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khanna</surname><given-names>A.</given-names></name><name name-style="western"><surname>Leighton</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lee Wong</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Symptoms of PBC - pathophysiology and management</article-title><source>Best Pract Res Clin Gastroenterol</source><volume>34–35</volume><year>2018</year><fpage>41</fpage><lpage>47</lpage><pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.bpg.2018.06.007</pub-id><pub-id pub-id-type="pmid">30343709</pub-id></element-citation></ref><ref id="bib112"><label>112</label><element-citation id="sref112" publication-type="journal"><person-group person-group-type="author"><collab>European Association for the Study of the L</collab></person-group><article-title>EASL Clinical Practice Guidelines on genetic cholestatic liver diseases</article-title><source>J Hepatol</source><volume>81</volume><year>2024</year><fpage>303</fpage><lpage>325</lpage><pub-id pub-id-type="pmid">38851996</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.jhep.2024.04.006</pub-id></element-citation></ref><ref id="bib113"><label>113</label><element-citation id="sref113" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Konkwo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chowdhury</surname><given-names>S.</given-names></name><name name-style="western"><surname>Vilarinho</surname><given-names>S.</given-names></name></person-group><article-title>Genetics of liver disease in adults</article-title><source>Hepatol Commun</source><volume>8</volume><year>2024</year><pub-id assigning-authority="pmc" pub-id-type="doi">10.1097/HC9.0000000000000408</pub-id><pub-id pub-id-type="pmcid">PMC10984672</pub-id><pub-id pub-id-type="pmid">38551385</pub-id></element-citation></ref><ref id="bib114"><label>114</label><element-citation id="sref114" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>M.</given-names></name><name name-style="western"><surname>Allington</surname><given-names>G.</given-names></name><name name-style="western"><surname>Vilarinho</surname><given-names>S.</given-names></name></person-group><article-title>Genomic medicine for liver disease</article-title><source>Hepatology</source><volume>76</volume><year>2022</year><fpage>860</fpage><lpage>868</lpage><pub-id pub-id-type="pmid">35076957</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1002/hep.32364</pub-id><pub-id pub-id-type="pmcid">PMC10460497</pub-id></element-citation></ref><ref id="bib115"><label>115</label><element-citation id="sref115" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ewans</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Minoche</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Schofield</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Whole exome and genome sequencing in mendelian disorders: a diagnostic and health economic analysis</article-title><source>Eur J Hum Genet</source><volume>30</volume><year>2022</year><fpage>1121</fpage><lpage>1131</lpage><pub-id pub-id-type="pmid">35970915</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1038/s41431-022-01162-2</pub-id><pub-id pub-id-type="pmcid">PMC9553973</pub-id></element-citation></ref><ref id="bib116"><label>116</label><element-citation id="sref116" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schmitz-Abe</surname><given-names>K.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Rosen</surname><given-names>S.M.</given-names></name><etal/></person-group><article-title>Unique bioinformatic approach and comprehensive reanalysis improve diagnostic yield of clinical exomes</article-title><source>Eur J Hum Genet</source><volume>27</volume><year>2019</year><fpage>1398</fpage><lpage>1405</lpage><pub-id pub-id-type="pmid">30979967</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1038/s41431-019-0401-x</pub-id><pub-id pub-id-type="pmcid">PMC6777619</pub-id></element-citation></ref><ref id="bib117"><label>117</label><element-citation id="sref117" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brzozowska</surname><given-names>N.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>L.Y.D.</given-names></name><name name-style="western"><surname>Khodzhaeva</surname><given-names>V.</given-names></name><etal/></person-group><article-title>Selection for somatic escape variants in SERPINA1 in the liver of patients with alpha-1 antitrypsin deficiency</article-title><source>Nat Genet</source><volume>57</volume><year>2025</year><fpage>875</fpage><lpage>883</lpage><pub-id pub-id-type="pmid">40065168</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1038/s41588-025-02125-1</pub-id><pub-id pub-id-type="pmcid">PMC11985350</pub-id></element-citation></ref><ref id="bib118"><label>118</label><element-citation id="sref118" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vilarinho</surname><given-names>S.</given-names></name></person-group><article-title>The interplay between germline and somatic variants in alpha-1 anti-trypsin deficiency liver disease</article-title><source>Nat Genet</source><volume>57</volume><year>2025</year><fpage>775</fpage><lpage>776</lpage><pub-id pub-id-type="pmid">40169790</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1038/s41588-025-02151-z</pub-id></element-citation></ref><ref id="bib119"><label>119</label><element-citation id="sref119" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chung</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bale</surname><given-names>A.E.</given-names></name><etal/></person-group><article-title>Hepatology Genome Rounds: an interdisciplinary approach to integrate genomic data into clinical practice</article-title><source>J Hepatol</source><volume>79</volume><year>2023</year><fpage>1065</fpage><lpage>1071</lpage><pub-id pub-id-type="pmid">37011712</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.jhep.2023.03.030</pub-id><pub-id pub-id-type="pmcid">PMC10523901</pub-id></element-citation></ref><ref id="bib120"><label>120</label><element-citation id="sref120" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nalbantoglu</surname><given-names>I.</given-names></name><name name-style="western"><surname>Misdraji</surname><given-names>J.</given-names></name></person-group><article-title>Approach to the liver biopsy diagnosis of adult cholangiopathies</article-title><source>Diagn Histopathology</source><volume>29</volume><year>2023</year><fpage>23</fpage><lpage>35</lpage></element-citation></ref><ref id="bib121"><label>121</label><element-citation id="sref121" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wendum</surname><given-names>D.</given-names></name><name name-style="western"><surname>Barbu</surname><given-names>V.</given-names></name><name name-style="western"><surname>Rosmorduc</surname><given-names>O.</given-names></name><etal/></person-group><article-title>Aspects of liver pathology in adult patients with MDR3/ABCB4 gene mutations</article-title><source>Virchows Arch</source><volume>460</volume><year>2012</year><fpage>291</fpage><lpage>298</lpage><pub-id pub-id-type="pmid">22331132</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1007/s00428-012-1202-6</pub-id></element-citation></ref><ref id="bib122"><label>122</label><element-citation id="sref122" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dombrowski</surname><given-names>F.</given-names></name><name name-style="western"><surname>Stieger</surname><given-names>B.</given-names></name><name name-style="western"><surname>Beuers</surname><given-names>U.</given-names></name></person-group><article-title>Tauroursodeoxycholic acid inserts the bile salt export pump into canalicular membranes of cholestatic rat liver</article-title><source>Lab Invest</source><volume>86</volume><year>2006</year><fpage>166</fpage><lpage>174</lpage><pub-id pub-id-type="pmid">16344857</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1038/labinvest.3700371</pub-id></element-citation></ref><ref id="bib123"><label>123</label><element-citation id="sref123" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marschall</surname><given-names>H.U.</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zollner</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans</article-title><source>Gastroenterology</source><volume>129</volume><year>2005</year><fpage>476</fpage><lpage>485</lpage><pub-id pub-id-type="pmid">16083704</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.gastro.2005.05.009</pub-id></element-citation></ref><ref id="bib124"><label>124</label><element-citation id="sref124" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frider</surname><given-names>B.</given-names></name><name name-style="western"><surname>Castillo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gordo-Gilart</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Reversal of advanced fibrosis after long-term ursodeoxycholic acid therapy in a patient with residual expression of MDR3</article-title><source>Ann Hepatol</source><volume>14</volume><year>2015</year><fpage>745</fpage><lpage>751</lpage><pub-id pub-id-type="pmid">26256905</pub-id></element-citation></ref><ref id="bib125"><label>125</label><element-citation id="sref125" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Poupon</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Balkau</surname><given-names>B.</given-names></name><name name-style="western"><surname>Eschwege</surname><given-names>E.</given-names></name><etal/></person-group><article-title>A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group</article-title><source>N Engl J Med</source><volume>324</volume><year>1991</year><fpage>1548</fpage><lpage>1554</lpage><pub-id pub-id-type="pmid">1674105</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1056/NEJM199105303242204</pub-id></element-citation></ref><ref id="bib126"><label>126</label><element-citation id="sref126" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jacquemin</surname><given-names>E.</given-names></name><name name-style="western"><surname>Hermans</surname><given-names>D.</given-names></name><name name-style="western"><surname>Myara</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Ursodeoxycholic acid therapy in pediatric patients with progressive familial intrahepatic cholestasis</article-title><source>Hepatology</source><volume>25</volume><year>1997</year><fpage>519</fpage><lpage>523</lpage><pub-id pub-id-type="pmid">9049190</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1002/hep.510250303</pub-id></element-citation></ref><ref id="bib127"><label>127</label><element-citation id="sref127" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pfister</surname><given-names>E.D.</given-names></name><name name-style="western"><surname>Jaeger</surname><given-names>V.K.</given-names></name><name name-style="western"><surname>Karch</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Native liver survival in bile salt export pump deficiency: results of a retrospective cohort study</article-title><source>Hepatol Commun</source><volume>7</volume><year>2023</year><pub-id assigning-authority="pmc" pub-id-type="doi">10.1097/HC9.0000000000000092</pub-id><pub-id pub-id-type="pmcid">PMC10069862</pub-id><pub-id pub-id-type="pmid">36995996</pub-id></element-citation></ref><ref id="bib128"><label>128</label><element-citation id="sref128" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bolia</surname><given-names>R.</given-names></name><name name-style="western"><surname>Goel</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>V.</given-names></name><etal/></person-group><article-title>Biliary diversion in progressive familial intrahepatic cholestasis: a systematic review and meta-analysis</article-title><source>Expert Rev Gastroenterol Hepatol</source><volume>16</volume><year>2022</year><fpage>163</fpage><lpage>172</lpage><pub-id pub-id-type="pmid">35051344</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1080/17474124.2022.2032660</pub-id></element-citation></ref><ref id="bib129"><label>129</label><element-citation id="sref129" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thompson</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Arnell</surname><given-names>H.</given-names></name><name name-style="western"><surname>Artan</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial</article-title><source>Lancet Gastroenterol Hepatol</source><volume>7</volume><year>2022</year><fpage>830</fpage><lpage>842</lpage><pub-id pub-id-type="pmid">35780807</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/S2468-1253(22)00093-0</pub-id></element-citation></ref><ref id="bib130"><label>130</label><element-citation id="sref130" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thompson</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Artan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Baumann</surname><given-names>U.</given-names></name><etal/></person-group><article-title>Interim results from an ongoing, open-label, single-arm trial of odevixibat in progressive familial intrahepatic cholestasis</article-title><source>JHEP Rep</source><volume>5</volume><year>2023</year><object-id pub-id-type="publisher-id">100782</object-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.jhepr.2023.100782</pub-id><pub-id pub-id-type="pmcid">PMC10338319</pub-id><pub-id pub-id-type="pmid">37456676</pub-id></element-citation></ref><ref id="bib131"><label>131</label><element-citation id="sref131" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loomes</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Squires</surname><given-names>R.H.</given-names></name><name name-style="western"><surname>Kelly</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Maralixibat for the treatment of PFIC: long-term, IBAT inhibition in an open-label, Phase 2 study</article-title><source>Hepatol Commun</source><volume>6</volume><year>2022</year><fpage>2379</fpage><lpage>2390</lpage><pub-id pub-id-type="pmid">35507739</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1002/hep4.1980</pub-id><pub-id pub-id-type="pmcid">PMC9426380</pub-id></element-citation></ref><ref id="bib132"><label>132</label><element-citation id="sref132" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miethke</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Moukarzel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Porta</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Maralixibat in progressive familial intrahepatic cholestasis (MARCH-PFIC): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial</article-title><source>Lancet Gastroenterol Hepatol</source><volume>9</volume><year>2024</year><fpage>620</fpage><lpage>631</lpage><pub-id pub-id-type="pmid">38723644</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/S2468-1253(24)00080-3</pub-id></element-citation></ref><ref id="bib133"><label>133</label><element-citation id="sref133" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Vries</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bolier</surname><given-names>R.</given-names></name><name name-style="western"><surname>Goet</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Fibrates for itch (FITCH) in fibrosing cholangiopathies: a double-blind, randomized, placebo-controlled trial</article-title><source>Gastroenterology</source><volume>160</volume><year>2021</year><fpage>734</fpage><lpage>743 e736</lpage><pub-id pub-id-type="pmid">33031833</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1053/j.gastro.2020.10.001</pub-id></element-citation></ref><ref id="bib134"><label>134</label><element-citation id="sref134" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Corpechot</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chazouilleres</surname><given-names>O.</given-names></name><name name-style="western"><surname>Rousseau</surname><given-names>A.</given-names></name><etal/></person-group><article-title>A placebo-controlled trial of bezafibrate in primary biliary cholangitis</article-title><source>N Engl J Med</source><volume>378</volume><year>2018</year><fpage>2171</fpage><lpage>2181</lpage><pub-id pub-id-type="pmid">29874528</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1056/NEJMoa1714519</pub-id></element-citation></ref><ref id="bib135"><label>135</label><element-citation id="sref135" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nagasaka</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yorifuji</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hirano</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Effects of bezafibrate on dyslipidemia with cholestasis in children with familial intrahepatic cholestasis-1 deficiency manifesting progressive familial intrahepatic cholestasis</article-title><source>Metabolism</source><volume>58</volume><year>2009</year><fpage>48</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">19059530</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.metabol.2008.08.005</pub-id></element-citation></ref><ref id="bib136"><label>136</label><element-citation id="sref136" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pfister</surname><given-names>E.D.</given-names></name><name name-style="western"><surname>Dröge</surname><given-names>C.</given-names></name><name name-style="western"><surname>Liebe</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Extrahepatic manifestations of progressive familial intrahepatic cholestasis syndromes: presentation of a case series and literature review</article-title><source>Liver Int</source><volume>42</volume><year>2022</year><fpage>1084</fpage><lpage>1096</lpage><pub-id pub-id-type="pmid">35184362</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1111/liv.15200</pub-id></element-citation></ref><ref id="bib137"><label>137</label><element-citation id="sref137" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dröge</surname><given-names>C.</given-names></name><name name-style="western"><surname>Keitel</surname><given-names>V.</given-names></name></person-group><article-title>Angeborene Cholestasesyndrome im Erwachsenenalter: Relevantes für Diagnostik und Therapie</article-title><source>Die Gastroenterologie</source><volume>18</volume><year>2023</year><fpage>377</fpage><lpage>384</lpage></element-citation></ref></ref-list><sec id="appsec1" sec-type="supplementary-material"><title>Supplementary data</title><p id="p0270">The following are the Supplementary data to this article:<supplementary-material content-type="local-data" id="mmc1" orientation="portrait" position="float"><caption><title>Multimedia component 1</title></caption><media orientation="portrait" position="float" xlink:href="mmc1.pdf" xmlns:xlink="http://www.w3.org/1999/xlink"><alt-text>Multimedia component 1</alt-text></media></supplementary-material></p></sec><fn-group><fn id="d36e299"><p id="ntpara0010t">Author names in bold designate shared co-first authorship</p></fn><fn fn-type="supplementary-material" id="appsec2"><p id="p0275">Supplementary data to this article can be found online at <ext-link ext-link-type="uri" id="intref0010" xlink:href="https://doi.org/10.1016/j.jhepr.2025.101625" xmlns:xlink="http://www.w3.org/1999/xlink">https://doi.org/10.1016/j.jhepr.2025.101625</ext-link>.</p></fn></fn-group></back></article>